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Abstract
Panic disorder (PD) is a severe anxiety disorder that is characterized by recurrent panic attacks 
(PA), which can be unexpected (uPA, i.e., no clear identifiable trigger) or expected (ePA). Panic 
typically involves an abrupt feeling of catastrophic fear or distress accompanied by physiological 
symptoms such as palpitations, racing heart, thermal sensations, and sweating. Recurrent uPA and 
ePA can also lead to agoraphobia, where subjects with PD avoid situations that were associated 
with PA. Here we will review recent developments in our understanding of PD, which includes 
discussions on: symptoms and signs associated with uPA and ePAs; Diagnosis of PD and the new 
DSM-V; biological etiology such as heritability and gene x environment and gene x hormonal 
development interactions; comparisons between laboratory and naturally occurring uPAs and 
ePAs; neurochemical systems that are associated with clinical PAs (e.g. gene associations; targets 
for triggering or treating PAs), adaptive fear and panic response concepts in the context of new 
NIH RDoc approach; and finally strengths and weaknesses of translational animal models of 
adaptive and pathological panic states.
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Section 1: Preface
The literature describing Panic Disorder (PD) is extensive and dates back many decades 
prior to PD being defined as a specific diagnostic syndrome in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM III) in 1980. Although this review will not exhaustively 
address every aspect of PD, our aim here is to discuss the key concepts that have shaped our 
understanding of this illness, provide succinct evaluation of the present knowledge, and 
define a few areas of gaps in knowledge for future research. To this end, in section 2 we will 
initially discuss the cognitive and physiological symptoms that occur during panic attacks 
(PAs), and the criteria for panic disorder diagnosis in the Diagnostic and Statistical Manual 
of Mental Disorders V (DSM-V). In section 3 we will discuss the emerging empirical 
evidence supporting a biological basis for recurrent PAs in PD that will include discussion 
on heritability, and how there may be gene x environment and gene x hormonal 
development interactions that explain post-adolescent onset and higher prevalence of PD in 
women. Section 4 contains a review of the large body of work on the many laboratory 
methods of inducing PAs and how they provide insight into potential naturalistic triggers of 
uPAs and ePAs. Section 5 introduces the neural circuits implicated in naturally occurring 
and laboratory induced PAs, and how these neural circuits compare with adaptive panic and 
fear circuitry as it is emerging in the new NIH RDoc system. Section 6 will then discuss 
neurochemical systems implicated in PD through clinical studies involving gene 
associations and pharmacological triggers/treatments associated with those systems. Section 
7 will assess strengths and weaknesses of translational animal models of adaptive panic and 
attempts to model pathological panic with deep brain stimulation or using trait approaches 
such as genetic knockout and systems biology approaches using interoceptive and 
exteroceptive panicogenic stimuli. Finally, Section 8 will address gaps in knowledge and 
future directions to advance our understanding of the etiology, triggers, and subtypes of PAs 
that could lead to novel therapeutic advances.
Section 2 – Panic Disorder and Panic Attacks: Symptoms, Signs, 
Diagnostic Criteria (DSM-I through V)
Within the anxiety disorder spectrum, recurrent PAs are the hallmark of diagnosis for PD, 
but PAs can also frequently occur in other severe anxiety disorders such as post-traumatic 
stress disorder and phobias (Jensen et al., 1998), and less frequently associated with other 
anxiety disorders such as generalized anxiety and obsessive compulsive disorders (Gorman 
et al., 1985; Liebowitz et al., 1985a), or pure depressive disorders (Cowley et al., 1987). The 
recurrent PAs are categorized in the DSM-V as being either unexpected (also called 
spontaneous) (uPA), or expected (ePA). The uPAs occur in the absence of a clear external 
trigger that can be identified by the subject and are estimated to account for ~40% of PAs 
(Shulman et al., 1994). Another subtype, ePAs occur where an external cue (e.g., situation 
where uPAs have occurred, or when confronted with a generally feared phobic situation or 
stimulus) is associated with the induction of the PA (Shulman et al., 1994). Collectively, 
recurrent PAs (either uPA and ePA) can lead to agoraphobia, which is a conditioned 
avoidance response that occurs when people with PD begin to fear situations that are 
associated with PA or where escape might be difficult or help might not be available (e.g., 
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planes, elevators etc.) if a PA were to occur. The majority of agoraphobia diagnoses occur in 
the presence of PD, but it is important to note that it can occur independently [see review 
(Wittchen et al., 2010)]. Therefore, in the DSM-V, agoraphobia is considered an 
independent anxiety disorder.
Both uPAs and ePAs are comprised of an abrupt surge of symptoms that typically consist of 
cognitive symptoms like catastrophic fear of dying and/or losing control alongside 
autonomic-related symptoms such as palpitations, racing heart, hot flashes (heat sensations), 
and sweating. Other physical symptoms may include increased respiratory drive, 
paresthesias (numbing or tingling sensations), dizziness, and nausea. In the DSM-V, a PA 
consists of 4 or more of the 13 possible symptoms; two of these are cognitive/fear symptoms 
and eleven are physical symptoms. Typical PAs peak within ~10 min, have a duration of 
25–45 min, and can occur during calm or anxious states (Taylor et al., 1986; Margraf et al., 
1987; de Beurs et al., 1994). Even though PAs can occur in calm or anxious states, the 
severity and duration of the PA appears to be affected by such state-dependent variables. For 
instance, uPAs that occurred during relaxation therapy peaked within ~3 min and subsided 
shortly afterwards (Cohen et al., 1985), and in one study situational ePAs were considered 
more severe than uPAs (Margraf et al., 1987). Although PAs do occur at night, it is 
important to note that PD subjects are much more vulnerable to having PAs when awake, 
and PA vulnerability is highest from 10AM to 4PM, with 2PM – 4PM being the highest 
incidence (see Figure 1). This vulnerability coincides with many neurochemical systems 
becoming more active, such as the sympathetic nervous system, central serotonergic and 
noradrenergic systems, as well as increases in plasma concentrations cortisol, and 
norepinephrine (discussed further in sections 4d, and 6).
Although some symptoms associated with PAs are more common than others, the specific 
cognitive and physical symptoms associated with uPAs and ePAs can vary greatly across PD 
subjects and during different episodes of PD within the same subject. Using a PA 
questionnaire on 212 PD subjects, Cox and colleagues found that cognitive symptoms had 
the highest frequency/severity rating, but it is important to note that these cognitive 
symptoms were not associated with DSM-V criteria for PD, and are arguably more 
associated with agoraphobia (i.e., feeling helpless, thoughts of escape, difficulty 
concentrating, and fear of causing a scene). In regards to the 13 accepted cognitive/physical 
symptoms associated with PD, heart/autonomic disturbance related symptoms (i.e., 
tachycardia > heart pounding > sweating) were ranked as being most severe/prevalent; 
followed by cognitive symptoms (i.e., fear of dying > feelings of unreality > fear of going 
crazy > and fear of losing control); then respiratory-related symptoms (i.e., dizziness > 
dyspnea); and finally symptoms such as nausea and parasthesias ranked as being least 
frequent and severe. They also noted that there were differences in presentation of 
symptoms that is suggestive of subtype of PA, that could be related to etiology or trigger and 
is supportive of the causes of PD and repeated PA’s being heterogenous (Cox et al., 1994).
Consistent with Cox’s article, in a recent review by Craske and colleagues (Craske et al., 
2010), heart-related symptoms were the most common during a PA [e.g., heart pounding 
97%, tachycardia 86.1%, palpitations 78%], with the other 11 physical symptoms having a 
prevalence rate ranging from ~35–95%. Even though heart-related symptoms are most 
Johnson et al. Page 3
Neurosci Biobehav Rev. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
commonly reported during a PA, the specific heart-related symptom reported varies. It is 
also important to note that these are self-reported symptoms and not objective measures of 
vital signs. Therefore, caution should be taken when interpreting these symptoms (e.g., a 
subjective feeling of tachycardia could be a more forceful “pounding” heart contraction). In 
objective measures of PAs, cardiac related symptoms also varied. For instance in 1987, 
Margraf and colleagues asessed naturally occurring PAs in 27 PD and 19 control subjects 
that wore ambulatory heart rate monitors for 3 days. The PD subjects reported 175 PAs that 
consisted primarily of self-reported palpitations, dizziness, sweating, and chest pain. They 
also noted that situational or ePAs were more severe than uPAs, and that heart rate increases 
(tachycardia) did not occur in uPAs, but did occur in ePAs and preceded ePAs by ~15 min 
(Margraf et al., 1987). Another more recent study objectively assessed a total of 13 PAs in 4 
male and 5 female PD subjects using ambulatory monitoring of heart rate, respiratory 
activity, and skin conductance (Meuret et al., 2005). The median length of the 13 PAs was 8 
min, with ~38% occurring when alone, ~23% with a friend, ~39% with family; overall, 
~69% were unexpected. In this study, significant cardiorespiratory changes were occurring 
as early as 45 min prior to the onset of the PA. Specifically, tachycardia and bradypnea (and 
a subsequent drop in end tidal CO2) occurred around 50 min prior to PA. Twenty min prior 
to the PA, a decrease in tidal volume occurred that was followed by a marked increase in 
end tidal pCO2. In this study, a significant tachycardia was noted during the PA, as well as 
an increase in tidal volume and decrease in end tidal pCO2. Yet, the authors note that only a 
few of the subjects had a dramatic tachycardia during the PA. The severity of end tidal pCO2 
during the PA was correlated with symptoms such as anxiety, fear of dying, and chest pain, 
whereas as the severity of the tachycardia was associated with symptoms such as fear of 
losing control and faintness. Although skin conductance did not vary prior to or during the 
PA, it was generally higher than non-PA periods at similar times of day. In other studies 
assessing ambulatory heart rate in PD patients with naturally occurring PAs also report such 
variability in symptoms reporting that tachycardia occurred in 3 out of 8 PAs (38%) (Barr 
Taylor et al., 1982), and in 19 of 33 PAs (58%) (Taylor et al., 1986). Thus, although the 
symptoms that occur during uPAs and ePAs are strongly suggestive of disrupted autonomic 
activity (e.g., heart related symptoms, sweating and heat sensation, light headedness or 
faintness, and abdominal distress), the symptom themselves are largely heterogeneous in 
nature (even heart-related symptoms), and may precede and/or occur during naturally 
occurring PAs.
Although fear-associated cognitive symptoms are present in the majority of PAs, some 
groups have hypothesized that there is evidence that the fear-associated cognitive symptoms 
are not always present in some PA despite 4 or more physical symptoms being present. 
Beitman and colleagues studied 32 subjects with angiographically normal coronary arteries 
that met the criteria for PD, and of those subjects, 13 (41%) reported no fear (i.e., 
specifically fear of dying or going crazy) during the most recent PA, but did report 
significant discomfort (Beitman et al., 1990). Therefore, this type of PA is often referred to 
as a non-fear PA. When comparing symptoms of non-fear PA and fear PA, there was no 
difference in shortness of breath, chest pain, and palpitations; but hot flashes, paresthesias, 
and derealization (Beitman et al., 1990) were higher in fear PAs. In a national comorbidity 
survey, Chen and colleagues found that 589 subjects out of 8098 respondents met the 
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diagnostic criteria for lifetime PA (Chen et al., 2009). Among the 589 subjects, 176 (30%) 
met the criteria for a non-fear PA. In this instance when comparing of symptoms of non-fear 
PA and fear PA, there was no difference in the symptoms such as hot flashes, and 
paresthesias, but PD subjects with fear PAs had significantly higher incidence of 
depersonalization, shortness of breath, smothering, trembling, and a slightly higher 
incidence of heart pounding. The PD subjects with fear PAs were also almost twice as likely 
to develop agoraphobia and to abuse alcohol or drugs. Thus, even if meeting 4 or more 
symptoms criteria of the DSM-V, PAs in the absence of the cognitive fear appear to be less 
likely to results in recurrent ePAs, agoraphobia, substance abuse, and other comorbidities 
such as depression.
To further understand the biology mediating Pas, more studies are needed to assess 
cognitive symptoms and autonomic tone (e.g., heart rate, heart rate variability, blood 
pressure, skin sweating and flushes, and plasma catecholamines), and endocrine responses 
(e.g, cortisol) during naturally occurring PAs, and prospective studies in high risk 
populations (e.g, monozygotic twin or first degree relatives of PD subjects) during the 
premorbid period, i.e., prior to having had repeated PAs. The current knowledge 
surrounding autonomic tone will be further addressed in section 4 when discussing potential 
PA triggers and laboratory assessments of autonomic tone.
Section 3 – Empirical Evidence for Biological Basis of Recurrent Panic 
Attacks
3a. Heritability
Anxiety disorders are a heterogeneous classification that have a lifetime prevalence of about 
20% in the general population Among the distinct syndromes that have been delineated 
based on clinical presentations, Panic Disorder represents one of the most severe anxiety 
disorders where recurrent uPAs and ePAs occur (DSM-V, 2013). Current estimates are that 
about 7–10% of the population experience occasional PAs and the prevalence of PD in the 
general population is ~2–5% (Goodwin et al., 2005; Kessler et al., 2006). Although the 
etiology of PD is largely unknown, there is a strong heritability in first degree relatives 
(~11%) and monozygotic twins (30–40%) [see meta-analysis and reviews by (Hettema et al., 
2001; Schumacher et al., 2011)]. However, as discussed in section 6, Maron and colleagues 
conducted a meta-analysis of the use of linkage and candidate genes in association studies, 
which have found over 1000 polymorphisms and 350 candidate genes, for their association 
with PD (Maron et al., 2010). Although there are several promising, replicable candidate 
genes, most studies produced inconsistent results. Therefore, even though there is a strong 
genetic predisposition for PD in monozygotic twins and first degree relatives, the specific 
genes associated with PD and recurrent PAs may be more heterogeneous than the symptoms 
associated with PAs, and there is most likely multiple gene polymorphisms that may 
contribute small but cumulative risks for the symptoms and presentation of PD. Another 
consideration is gene x environment and gene x hormonal development interactions which is 
discussed in the following subsections in section 3.
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3b. Age of onset (gene x hormonal development and gene x environment considerations)
Another informative clue to PD etiology is the age of onset, which has a mean age range at 
diagnosis from 22–23 years in US population (DSM-V, 2013), but the incidence of PAs and 
PD show a gradual increase during adolescence [(Reed and Wittchen, 1998) see Figure 1] 
that coincides with sex hormone surges and sexual maturation that begins at ~10–12 and 
ends at ~15–17 years of age [see review (Kessler et al., 2010)]. This developmental stage is 
accompanied by critical cortical growth and remodeling which begins in pre-adolescence 
and continues to develop until early adulthood when PAs and PD typically get diagnosed 
(see Figure 2a). This developmental stage is associated with the development of greater 
cognitive maturation including more complex reasoning, a stronger urge for independence, 
and interest in the opposite sex. The specific cortical events that occur during this period is 
beyond the scope of this review, but overall there is massive pruning of excitatory synapses 
in the prefrontal cortex that occurs in pre-adolescence and continues until the offset of 
puberty when maximal inhibitory interneuronal activity begins to occur (see Figure 2b) 
(Huttenlocher, 1979, 1984; Spear, 2000; Insel, 2010). Of particular relevance to anxiety, 
fear, and panic states, there is also evidence that this is a critical period for development of 
connectivity of the prefrontal cortex with the amygdala and brain stem centers (Gee et al., 
2012; Gee et al., 2013a; Gee et al., 2013b), all structures that are critical for developing fear 
and panic, and heavily implicated in anxiety disorders such as PTSD and PD. This 
connectivity with the prefrontal cortex appears to be critical for extinction of fear memories 
and preventing over-generalization of threatening cues (Kheirbek et al., 2012). The 
development and synchronization of this circuit is altered by stress and is discussed further 
in section 5. There is evidence that the ventromedial PFC (vmPFC) is also hypoactive in 
anxiety pathology, which can lead to loss of tonic inhibition of the amygdala or subcortical 
panic-generating brain regions such as the perifornical hypothalamus (PeF) and dorsal 
periaqueductal gray (DPAG), which could contribute to the onset of PAs and PD. 
Furthermore, section 5 will also discuss how cognitive behavioral therapies (CBT) may be 
effective for treating PA and PD by enhancing vmPFC activity and restoring functional 
connectively with subcortical fear and panic centers.
Another striking feature of PD is that, compared to men, women show earlier age of onset 
(Reed and Wittchen, 1998) and are twice as likely as males to develop PD [see Figure 2a 
(Reed and Wittchen, 1998; Sheikh et al., 2002)]. The initiation of fluctuating sex steroid 
hormones over the menstrual cycle in women [see review (Nillni et al., 2011)] could be an 
important factor that contributes to the higher rates of PA and PD in women, but other 
factors such as early life stress or higher incidence of trauma such as sexual abuse or 
domestic violence in women could also account for this vulnerability. Evidence supporting a 
hormonal contribution includes a study demonstrating that female PD subjects with 
agoraphobia reported experiencing premenstrual exacerbations in anxiety symptoms, a 
pattern which could increase the rate of ePAs and contribute to the development of 
agoraphobia in these subjects (Breier et al., 1986). Furthermore, there is evidence that fear 
extinction retention is reduced during some phases of the menstrual cycle and increased in 
other phases (Milad et al., 2010; Zeidan et al., 2011). Thus fluctuating sex hormones in 
women may predispose them to persistent emotional trauma (e.g., PTSD) during aversive 
Johnson et al. Page 6
Neurosci Biobehav Rev. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
events. Finally, women with a genetic predisposition for PD may be more vulnerable to 
ePAs and agoraphobia during specific phases of the menstrual cycle.
In addition to gene X hormone interactions, pre-existing developmental anxiety states and 
early life stress are also environmental factors to consider in the etiology of PD. In 
structured psychiatric interviews of 55 subjects meeting DSM-III criteria of PD, childhood 
separation disorder was comorbid in 17% of the subjects (Breier et al., 1986).
Section 4 – Panic Attacks Triggers: Laboratory and Potential Natural 
Triggers
4a. Adaptive panic and fear responses to threatening external and internal sensory events
Normally a panic response is an adaptive survival response (Stein and Bouwer, 1997) that is 
conceptualized as a perception of an imminent external or exteroceptive threat (e.g., attack 
by a predator or conspecific aggressive male) that produces cognitive symptoms of fear or 
panic that are accompanied by: 1) somatic motor behavioral responses (i.e., fight or flight); 
2) coordinated autonomic sympathetic responses and parasympathetic withdrawal to 
increase cardiovascular activity; 3) increased respiratory activity to oxygenate the body; and 
4) hormonal responses [i.e., epinephrine, hypothalamic-pituitary-adrenal (HPA) axis cortisol 
response, etc.] to mobilize energy stores and suppress the immune system. Yet, internal 
sensory input (interoceptive) can also signal life threatening events and can elicit cognitive 
fear and physical symptoms similar to PAs (Street et al., 1989; Ehlers and Breuer, 1996). 
For instance, hypercapnia, which is a condition associated with increased plasma levels of 
CO2 resulting in peripheral and central acidosis initially just increases breathing to “blow 
off” excess CO2 [see review (Guyenet et al., 2010)]. However, if the hypercapnia becomes 
too severe, a feeling of suffocation and smothering arises and elicits additional symptoms 
very similar to a PA (Forsyth and Eifert, 1998; Forsyth et al., 2000b; Bailey et al., 2005). 
Most evidence supports that ePAs are provoked by exteroceptive threats (e.g., situations 
where PAs have occurred leading to anticipatory anxiety, or non-related stressful stimuli), 
but there is growing evidence that suggests that uPAs may be provoked by non-life threating 
changes in interoceptive internal sensory information that subjects are normally not aware 
of, but may yet elicit a response in PD subjects. Hence, the uPA appears to come out of 
nowhere, but may have detectable, subthreshold interoceptive cues that can be detected with 
appropriate monitoring of uPAs. Unfortunately, very few such studies have been conducted 
due to the obvious difficulties of timing and monitoring uPAs.
In this section we will initially discuss uPAs; laboratory studies that give insight into 
potential naturally occurring interoceptive triggers and the neural circuitry that is thought to 
be critical for the sensory input and cognitive and motor output. We will then discuss ePAs 
triggers and neural circuitry for ePAs. Finally, we will compare PAs to normal panic and 
fear circuitry in the NIH RDoc.
4b. Unexpected panic attacks: interoceptive triggers
In the de Beurs study mentioned in section 2, the investigators continuously monitored 
naturally occurring PAs in 97 subjects with PD + agoraphobia, with the subjects reporting 
Johnson et al. Page 7
Neurosci Biobehav Rev. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the context in which they had their PA; 53% of the PAs occurred in relatively non-
threatening and not agoraphobic contexts (i.e., 45% occurred at home and 8% while visiting 
a friend) (de Beurs et al., 1994). Thus, the PA was seemingly unprovoked or unexpected. So 
what was triggering these uPAs? One of the most consistent abnormalities seen in subjects 
with panic disorder under laboratory conditions is that they are hyper-responsive to normal 
interoceptive cues (Hoehn-Saric et al., 2004; Pollock et al., 2006) and are vulnerable to 
displaying panic attacks in response to mild interoceptive cues such as hypertonic 0.5M 
NaLac infusions (Liebowitz et al., 1984; Liebowitz et al., 1985b), inhalation of gas with 
increased CO2 concentration (Gorman et al., 1994), which normally do not elicit panic 
attacks in healthy controls. For instance, in 1984, Gorman and colleagues exposed 12 
patients with a DSM-III PD diagnosis and 4 healthy subjects to 5%CO2, 0.5M sodium 
lactate (NaLac) intravenous infusions or had them hyperventilate room air, and found that in 
PD subjects 7/12 (58%) had a PA to CO2, 8/12 (67%) to NaLac, and 3/12 (25%) to 
hyperventilation (Gorman et al., 1984). This suggests that PD patients are either 
hypersensitive or hyper-responsive to these interoceptive physiological stimuli that would 
normally signal a life-threatening event, and elicit an adaptive ‘panic’ response, only when 
severely altered. Therefore, the initial pathology in these patients appears to be an alteration 
somewhere in the central neural pathways that normally regulate the initiation of an adaptive 
panic respons only in response to a life-threatening interoceptive stimuli, thus rendering the 
PD patients susceptible to ‘unexpected’ panic symptoms when exposed to ordinarily mild 
interoceptive stressors (Vickers and McNally, 2005). In the following subsections, we will 
discuss the different interoceptive sensory challenges that provoke panic attacks, and 
compare and contrast between them in regards to the sensory routes for these stimuli, the 
brain circuits that respond to them, the resulting cognitive perception of the challenge, and 
the motor (i.e., somatomotor, visceromotor and metabolic/endocrine) responses. We will 
discuss both clinical and preclinical data.
4bi. Hypo- or hyper-ventilation induced PAs, suffocation, and respiratory abnormalities in 
PD
Subtle increases in CO2 in the blood (i.e., hypercapnia) caused by hypoventilation or 
holding one’s breath result in acidosis in peripheral and central brain structures that initially 
results in an increase in respiration activity to help “blow off” excess CO2 without much 
conscious awareness of the event [see review (Guyenet et al., 2010)]. However, if CO2 
levels continue to increase, there is a sense of “suffocation” and additional physiologic 
responses are initiated, including adaptive behavioral and autonomic responses. For 
instance, having healthy human subjects inhale hypercarbic gas (7.5% CO2 with normoxic 
air and balanced N2) for 20 min (compared to normal air) increased cognitive symptoms 
such as feelings of fear and being paralyzed, but also an urge to leave. Additional symptoms 
included self-reported breathlessness and cardiovascular symptoms (i.e., systolic blood 
pressure increase and tachycardia) (Bailey et al., 2005). Woods and colleagues also exposed 
healthy subjects to 7.5%CO2 in normoxic air for 15 min which, compared to control air, led 
to an increase in subjective reports of fear, anxiety, and nervousness in a visual analogue 
scale (VAS: no report of fear of losing control or going crazy), as well as physical symptoms 
associated with PA criteria in DSM-V such as sweating, palpitations, paresthesias, choking 
feeling, and dyspnea (Woods et al., 1988). Similar to Gorman and colleagues findings in 
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1984, Woods and colleagues then exposed healthy and PD subjects to 5% CO2 with 
normoxic air for 15 min, which in healthy subjects only increased nervousness, faintness, 
and dyspnea, and elicited no PAs, but did provoke a PA in 3/5 (60%) males and 4/9 (44%) 
female PD subjects. Compared to healthy subjects, PD subjects that experienced a PA had 
greater fear and anxiety in VAS, as well as greater dyspnea, fear of losing control, 
palpitations, sweating, but no differences in paresthesias, faintness, or dizziness. In studies 
using objective cardiovascular and endocrine measures, the 5% CO2 challenge increased 
systolic blood pressure and respiration rate in both healthy and PD subjects that had a PA, 
but PD subjects that had a PA did have a greater heart rate response. It is important to note 
that PD subjects that did not have a PA to CO2 did not have a significant increase in systolic 
blood pressure, or an increase in heart rate. In a similar study, PD subjects showed a 73.3% 
rate of mild fear (11/15) and a 40% PA rate (6/15) to 5%CO2 (Antony et al., 1997).
Hyperventilation is another method of altering acid-base homeostasis caused by blowing off 
excessive CO2 and inducing peripheral and central alkalosis (Friedman et al., 2006). Having 
PD subjects hyperventilate also induces PAs in some PD subjects, but this alkalosis seems to 
be less effective than acidosis in eliciting a PA in PD subjects. Hyperventilation provoked a 
PA in 3/12 PD subjects (25%) (Gorman et al., 1984), and in another study elicited mild fear 
in 20% of PD subjects (3/15), and no PAs (defined as moderate to strong fear response) 
(Antony et al., 1997). In other studies using a hyperventilation challenge, PD subjects had a 
PA (defined as 4 or more symptoms of a PA in the DSM-IV, with at least one cognitive fear 
symptom) response rate of 46% (6/13) and healthy controls 10% (1/10) in one study (Nardi 
et al., 1999), and PD response rates of 46% (16/35) compared to response rates of 7% (2/30) 
in healthy subjects in another study (Nardi et al., 2001). Specific physical symptoms were 
not reported, nor were objective autonomic and endocrine measures assessed. Overall, 
inducing acidosis, with hypercapnic gas inhalation (a suffocation cue) appears to be more 
effective in inducing PAs in PD subjects with an approximate response rate of 40%-60%, 
compared to hyperventilation which had PA rates in PD subjects ranging from 0–46%. 
Another method of inducing PAs in PD subjects is to intravenously administer doxapram, 
which stimulates peripheral chemoreceptors in the carotid bodies and indirectly alters 
activity in the respiratory centers of the brain stem to stimulate increases in respiration rate 
and tidal volume, mimicking hyperventilation. In a small study, 6 patients with PD 
(compared to 4 healthy subjects) had a greater increase in panic symptoms as measured by 
the Acute Panic Inventory following doxapram administration (Gutman et al 2005). They 
also assessed cortisol and the norepinephrine metabolite MHPG and found that both were 
elevated at baseline in PD subjects, and only cortisol increased post-doxapram, but there was 
no difference in this response due to different baseline levels. In an elegant study, Abelson 
and colleagues (1996) demonstrated that cognitive-behavioral therapy can reduce the 
severity of PA response to doxapram, despite similar levels of physiological activation, 
further supporting that it is not simply a hypersensitivity to a respiratory stimulus that results 
in a PA (Abelson et al., 1996).
Overall, this suggests that, in some cases, uPAs could be provoked by subtle CO2-related 
cues (PCO2, and peripheral and central acidosis) that signal air hunger and suffocation. The 
notion that uPAs could be triggered by small and non-threatening changes in peripheral and 
central acid-base homeostasis is suggested by the fairly consistent report of symptoms such 
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as dyspnea, feeling out of breath, or suffocating during such uPAs. Other evidence comes 
from a timely meta-analysis of baseline respiratory parameters in PD, that determined that 
PD was associated with higher baseline hyperventilation and rate of sighing which are both 
suggestive of an over-reaction to increases in acidosis, a suffocation signal (Grassi et al., 
2013). This hyper-reactivity to hypercapnia could be a relevant trigger of PAs in 
environmental settings where ambient CO2 levels are increasing such as people with asthma 
or obstructive lung diseases, and even physically healthy subjects with PD trapped in closed 
spaces such as an elevator with groups of people exhaling high levels of end tidal CO2 
(approximately 5–6% exhalation, compared to atmospheric concentrations of CO2 that are 
less that 0.05%).
In light of this evidence, in 1993, Donald Klein proposed a CO2 hypersensitivity theory of 
panic where a “false suffocation alarm” produces respiratory distress following by 
hyperventilation “to blow off” CO2, then uPA’s and an urge to flee (Klein, 1993). Klein 
compared the hypersensitivity to CO2 in PD as being the converse of Ondine’s curse which 
is a condition associated with episodes of apnea during sleep that can be fatal and may be 
related to a hyposensitivity to CO2. Thus PA’s in PD are argued as being due to a 
hypersensitivity to CO2 that triggers false suffocation, and potentially fatal sleep apnea’s in 
Ondine’s curse are a hyposensitivity to CO2 that fails to signal a real suffocation. Yet, some 
have countered that this hypothesis is not supported by empirical evidence (Ley, 1994), 
which is a valid point since the neural circuits and specific chemoreceptors critical for even 
normal CO2 induced breathing are complex and controversial, and as argued in a recent 
review are both most likely redundant and have heterogenous function (e.g., respiration 
drive, autonomic responses, somatic motor-related escape, and emotional arousal/panic) 
(Huckstepp and Dale, 2011). For instance, in the Huckstepp and Dale review they discuss 
the potential putative neural sites that are chemosensitive to CO2/pH which include: 1) 
medullary regions such as the PreBötzinger complex, retrotrapezoid nucleus, and raphe 
pallidus (contains serotonergic neurons) that mainly spinal cord projecting and are involved 
in respiratory drive; 2) midbrain/pontine regions such as the locus ceruleus (contains 
noradrenergic neurons), and dorsal raphe nucleus (contains serotonergic neurons) that are 
mainly forebrain projecting and are involved in arousal and vigilance; 3) hypothalamic 
regions such as the perifornical hypothalamus (contains orexin neurons) that are involved in 
arousal and is a panic-generating site in humans (see section 5); and 4) amygdala that is 
involved in fear associated memory acquisition. The specific types of chemoreceptors that 
are sensitive to CO2/pH are just as diverse [e.g., acid sensing ion channels (ASICs), 
connexin 26 (Cx26), and Twik related acid sensitive K+ (TASK) channels, etc] as is their 
expression within the brain, and thus are just as controversial. Additionally, the specific 
chemoreceptors that are critical for fully functional CO2 response (e.g., respiratory, 
cardiovascular, emotional) most likely require several different chemoreceptor types that 
have been shown to sense CO2/pH to be intact. If uPA’s were due to a hypersensitivity to 
CO2, it is odd that PA’s begin to emerge during adolescence (coinciding with cortical 
development) and not at birth like other CO2 related disorders such as Ondine’s curse and 
sudden infant death syndrome (SIDS). Another consideration is that the apnea episodes 
associated with Ondine’s curse occur at night, and the majority of PA’s associated with PD 
occur during wake periods. Thus, although the collective data suggest that baseline 
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respiration activity and hyperactive responses to changes in acid-base disruption are very 
informative about potential triggers of uPAs, a major flaw in the “false suffocation alarm 
hypothesis” is that PA responses to these interoceptive triggers range from 40–60% in most 
PD subjects, and as discussed in section 4biii, other non-CO2/pH-related interoceptive 
stimuli such as Na+ also triggers PA’s in 88% of PD patients, which suggests additional 
interoceptive and exteroceptive factors may be involved, and argues that PA vulnerability in 
the majority or all of PD patients is not simply a hypersensitivity to CO2/pH.
Another argument for a cognitive component to CO2-induced PAs comes from a study 
where healthy college students subjects inhaled air with either 13 or 20% CO2 eight 20 sec 
epochs spaced 60–180s apart (Forsyth et al., 2000a) whilst measuring both objective 
physiological variables (cardiovascular, skin conductance) and subjective psychological 
variables. Even in healthy subjects, repeated inhalations of 13% CO2 produced variable 
cognitive and physical symptoms differences such that clinically recognized subtypes of 
PA’s were present in only 75% of subjects, including the ‘prototypical’ fear and 
physiological symptoms in ~25%, ‘cognitive’ panic with only subjective psychological 
symptoms in ~25%, and ‘non-panic’ attacks where the objective physiological symptoms 
were present but no fear presented in ~25%. The prototypical and cognitive panic groups 
rated their symptoms as most severe and had the highest rating of a sense of 
uncontrollability. It is interesting to note that there was a sex difference such that 77.3% of 
the prototypical subtype responders were female whereas 75% of the non-panic subtype 
group were male.To attempt to explain the differences in fear and autonomic responses in 
the healthy subjects, Forsyth and colleagues asked participants to rate their perceived control 
they had over their bodily sensation produces following the CO2 challenges, and found that 
the group displaying the most severe panic responses also had the highest rating of a sense 
of uncontrollability, compared to the group that did not show pronounced panic responses. 
Thus, a reduced feeling of control of a situation or visceromotor responses in combination 
with additive changes in diverse internal sensory input that are different in their signaling 
pathways could create a “perfect storm” for a PA. An example of another interoceptive 
trigger of PAs is NaLac, which is discussed in section 4c and is a salt and lactic acid. 
Although lactate is thought to be the main panicogenic interoceptive cue, there are clinical 
data showing that sodium is an equally potent a panicogen. Another consideration of a 
“perfect storm” are subtle changes in interoceptive homeostasis in addition to pre-existing 
anxiety (non-agoraphobic cue related), and potentially even intake of fluids containing 
caffeine for instance (discussed in section 5).
4bii. Are CO2-induced PAs due to hyper-sensitivity to CO2 or hyper-responsive panic 
system?
In 1986, Woods and colleagues wanted to assess respiratory responses to hypercapnic gas 
between 14 medication-free PD subjects with agoraphobia and healthy subjects, to 
determine if there was an increase in respiratory drive in response to hypercapnia induced by 
a rebreathing technique. Similar to inhalation of hypercapnic gas, rebreathing induced 
greater anxiety and nervousness in an Analogue Scale, but there were no differences in their 
ventilatory responses, upon which they concluded that abnormal CO2-chemoreceptor 
sensitivity did not explain the increased anxiety-associated behavioral sensitivity PD 
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subjects (Woods et al., 1986). An alternative hypothesis is that PAs are a result of a hyper-
active panic response system where sensory input (both interoceptive and exteroceptive) 
converge on. This hypothesis is attractive in that it could explain how divergent sensory 
input such as interoceptive (CO2, Na+, lactic acidosis), and exteroceptive stimuli (situational 
cues, stressful events) lead to panic responses.
4biii. Sodium lactate induced PAs
In 1967, Pitts and McClure noted that during exercise, subjects with anxiety neurosis had 
developed anxiety symptoms that coincided with a rapid increases in plasma lactic acid 
(Jones and Mellersh, 1946), and hypothesized that lactic acid may trigger anxiety attacks 
(Pitts and McClure, 1967). They then recruited subjects that had severe feelings of anxiety 
on a near daily basis, and 10 of 16 symptoms similar to those used to define PAs now (e.g., 
fear, palpitations, dyspnea, and parasthesias). Infusing 0.5M racemic sodium lactate solution 
(NaLac) elicited anxiety attacks (defined as catastrophic fear with >5 physical symptoms) in 
13 out of 14 (93%) anxiety neurosis subjects and in 2 out of 10 (20%) healthy controls. The 
predominant physical symptoms most often reported were paresthesias, tremors, 
palpitations, dizziness, and dyspnea with tremors; palpitations, and paresthesias were ranked 
as most severe. A glucose saline infusion failed to induce anxiety attacks in any subject. 
Later studies using subjects with a now-recognized diagnosis of PD using the DSM-III, also 
observed that 0.5M NaLac challenge elicited PAs in the majority of PD subjects compared 
to healthy controls or other neuropsychiatric disorders. For instance, administering i.v. 
infusions of 0.5M NaLac to 24 PD subjects (no controls used) elicited PAs (defined as 
abrupt fear accompanied by physical symptoms associated with a PA such as palpitations 
and shortness of breath, and sweating) in 7/10 (70%) males and 7/14 (50%) females (Goetz 
et al., 1989).
Later studies determined that, at baseline, PD subjects (36 men and 40 women) had higher 
venous pH and lower PCO2 levels compared to controls (18 men and 4 women) (Gorman et 
al., 1986) and although 0.5M NaLac infusions induced an alkalosis and decreased PCO2 in 
all groups, there was no group x time interaction, nor were baseline differences in pH or 
PCO2 different between PD subjects that had a PA and those that did not. A subsequent 
study assessed arterial pH and PCO2 levels prior to and during a 0.5M NaLac challenge to 
12 PD and 8 control male subjects determined that only the 5 PD subjects that had a PA 
(42%) to NaLac had increased pH (alkalosis) and decreased PCO2 levels. However, this 
effect may have been due to an outlier in the scattergram which showed a PD subject that 
had a PA to NaLac with baseline alkalosis where pH>7.45 (pH 7.55 and ~PCO2 of 24mm 
Hg). Post-NaLac, only control subjects and PD subjects that did not have a PA were 
assessed due to cessation of infusion in PD patients that did panic. Consistent with 
Gorman’s findings, NaLac increased pH and decreased PCO2 levels in both controls and PD 
subjects, but they did observe significant group (but not group x time) effects on pH, and 
group x time effects on PCO2 which declined more severely in PD subjects independent of a 
PA. It is unfortunate that respiratory parameters were not assessed alongside these plasma 
variables since this may have explained the subtle differences in these studies. Overall, the 
significant baseline differences between PD and healthy subjects is consistent with higher 
baseline hyperventilation and rate of sighing as shown in a recent meta-analysis (Grassi et 
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al., 2013), but unlike a CO2 challenge in normoxic air, NaLac is a multisensory challenge 
(e.g, alkalosis, lactate itself, osmotic stress, or potentially even hypernatremia) and the 
specific sensory trigger or triggers associated with NaLac that provokes the PA is not 
entirely clear.
Previous clinical studies conducted on Panic Disorder patients suggest that increased 
sodium, not lactate or osmotic stress, may be the critical change for provoking panic attacks. 
Peskind and colleagues challenged 8 PD and 7 healthy subjects with i.v. infusions of 0.5M 
NaLac, hypertonic sodium chloride (NaCl), or isotonic NaCl, which respectively provoked 
PAs in 6/8 (75%), 7/8 (88%) and 0/8 (0%) subjects (Peskind et al., 1998), and noted that 
serum Na+ was equivalently increased following NaLac and hypertonic NaCl. They also 
noted that even though both produced PAs, only NaLac increased venous pH and decreased 
venous PCO2 concentrations, which suggests Na+ may be panicogen. Additionally NaLac 
and hypertonic NaCl both increased arginine vasopressin, but hypertonic (3%) NaCl caused 
a greater increase. Sodium bicarbonate (Gorman et al., 1989) provoked equivalent panic-
associated responses in Panic Disorder patients. Furthermore, 11 of 20 PD subjects (65%) 
were more likely to experience a PA in response to lactate dissolved in 0.9%NaCl versus 
lactate dissolved in 5%dextrose, which induced a PA in 4 of 20 PD subjects (20%) (George 
et al., 1995).
Overall, most evidence suggests that various interoceptive triggers such as lactate, sodium, 
CO2, etc. are capable of triggering PAs, but the response rate may depend on additional 
factors such as the anxiety state of the individual, cognitive coping skills, and the 
environment (e.g., agoraphobic situation). Yet another consideration is how much of the PA 
vulnerability to interoceptive challenges is attributed to environmental factors such as an 
occupation associated with higher stress. For instance, in healthy subjects, NaLac induces a 
PA in ~0–20% of the time, but higher anxiety states or cognitive bias in healthy control 
subjects in the absence of a diagnosis of PD or any other history of neuropsychiatric 
problems also appears to increase the likelihood of PAs in response to interoceptive stimuli 
such as NaLac. Yeragani and colleagues recruited 41 healthy subjects that consisted of 
medical and paramedical personnel, and informed them that the infusion they would receive 
may provoke a PAs if a person had a history of previous PAs (Yeragani et al., 1987). They 
found that a higher 1M NaLac solution dissolved in 5% glucose induced a PAs in 5/23 
(22%) males and 5/18 (28%) females, and noted that the responders had higher panic 
symptoms measured with a panic description scale (PDS), than non-responders. The 
common panic symptoms rated most severe were catastrophic fear and shortness of breath.
4biv. Sense of control on CO2 and NaLac-induced PAs in PD subjects
In healthy control subjects, heightened self-reported fear responses to 20 seconds of 20% 
CO2 inhalation is a strong predictor of the later development of spontaneous panic attacks 
(Schmidt and Zvolensky, 2007). Finally, healthy controls also show habituated autonomic 
and self-reported anxiety across sessions, but not within session, after repeated inhalation of 
air containing 20% CO2 (Forsyth et al., 2000a), suggesting that these sessions could be used 
to stabilize existing heightened anxiety sensitivity to changes in acid-base homeostasis that 
may occur from altered breathing during stress. Conversely, pairing a threatening 
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exteroceptive visual cue (i.e., snake photo), but not a neutral exteroceptive cue (i.e., flower 
photo) with a 20% CO2 exposure (unconditioned stimuli) leads to exacerbated autonomic 
responses and self-reports of anxiety in humans (Forsyth and Eifert, 1998). Thus, heightened 
anxiety sensitivity to interoceptive stimuli could lead to phobic avoidance responses 
depending on whether or not the environmental context was threatening (e.g., crowded room 
or heavy traffic) during mild acid-base disruption such as occurs during irregular breathing.
In PD subjects, the illusion of control over a panicogenic interoceptive challenge appears to 
alter the degree of anxiety response and potentially catastrophic cognitive fear symptoms. 
For instance, Sanderson and colleagues exposed 20 PD subjects to 15 min of 5.5% CO2 in 
normoxic air. The subjects were told that if a light came on they could turn a dial and 
decrease the amount of CO2 they would receive. The light turned on for the duration of CO2 
challenge for half of the subjects and never turned on for the other half. They were not told 
the dial would not actually decrease the CO2 flow. Compared to PD subjects that had an 
illusion of control, PD subjects that thought they could not control the CO2 flow rate 
reported more DSM-III panic symptoms, greater perceived anxiety, and rated that the event 
was more like a naturally occurring PA (Sanderson et al., 1988).
4c. Expected panic attacks: exteroceptive triggers and agoraphobia
Expected PAs differ from uPAs in that there is an external cue (e.g., situation where uPAs 
have occurred, or during stressful situations) that is associated with the induction of the PA 
(Shulman et al., 1994). As mentioned in uPA section, ~53% of naturally-occurring PAs 
occur in relatively non-threatening situations, but the remaining PAs occur in more stressful 
situations such as work (5%) or driving (11%), and the remaining 31% of PAs occur in 
typical agoraphobic situations (i.e., 13% shops, 9% in street, 6% restaurants, and 3% in 
public transportation) (de Beurs et al., 1994). Woods and colleagues exposed 18 medication-
free PD subjects with agoraphobia and paired 13 healthy subjects (most cases) to typical 
agoraphobic situations (e.g., parks, malls, restaurants, and bridges) and assessed subjective 
anxiety and physical symptoms and measured heart rate and blood pressure prior to and after 
exposure. They determined that PD subjects had higher anxiety, fear, and nervousness 
symptoms at baseline and greater physical symptoms such as palpitations, parasthesias, 
dyspnea (Woods et al., 1987). Post-exposure, 13 of 18 PD subjects reported having a PA 
while no PAs were reported in healthy subjects. Thus, if uPAs are the initial type of PA in 
PD, these could eventually become associated with contextual environmental cues where 
previous PAs have occurred, such as bridges, crowded spaces, or situations where rapid exit 
is difficult (Wilson and Hayward, 2005). This development of cognitive bias towards threat 
perception (McNally et al., 1990) and conditioning of fear responses to panic cues (van den 
Heuvel et al., 2005) could then lead to phobias which are the likely mechanisms underlying 
recurrent ePAs in later stages of the illness.
From a treatment perspective, the gold standard for assessing the effectiveness of a 
treatment for PD is its ability to reduce the frequency and severity of PAs, but another 
important factor that should be considered is avoidance behaviors associated with PD 
subjects that develop in agoraphobia [see Contextual Learning Section from (Gorman et al., 
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2000)]. Thus, an ideal medication and/or cognitive behavioral therapy (CBT) that reduces 
the frequency and severity of PAswould ideally also reduce phobic avoidance.
4d. Sympathetic, parasympathetic, and endocrine responses during adaptive panic
During a normal adaptive panic response, imminent threats elicit strong emotional responses 
that coincide with somatic motor responses (e.g, fight or flight), but also robust autonomic 
responses where key panic-generating brain regions (e.g., the PeF and DPAG which are 
discussed in detail in sections 5 and 7) increase blood pressure and heart rate, initiate heat 
dissipation (sweating and increased blood flow to skin), and suppress gastrointestinal 
activity. In order for the sympathetic nervous system to simultaneously induce a pressor and 
tachycardia response, the baroreflex (which is driven by the rise in blood pressure and 
initiates vagally-mediated, parasympathetic bradycardia) needs to be desensitized [see 
review (McDowall et al., 2006)]. Among the panic-generating brain regions, the PeF and 
DPAG are both capable of doing this. Most sympathetic responses occur from 
postganglionic release of norepinephrine directly onto target systems (e.g., heart and blood 
vessels), but in some cases epinephrine (and to a lesser extent norepinephrine) can also be 
released as a hormone into the blood stream to reach targets. In addition, there may be a 
hypothalamic-pituitary-adrenal (HPA) axis stress endocrine response where cortisol is 
released into the bloodstream to mobilize energy resources and suppress the immune system, 
especially if the threat is persistent. However, most PAs occur rapidly enough, or a PA 
immediately evokes an escape response such that HPA activation may not be engaged 
routinely during a recurrent PAs. Yet, even under normal conditions, not all stress-related 
stimuli initiate the same type of panic response, and in many instances interoceptive 
stressors do not seem to consistently initiate a significant HPA axis response. It has also 
been hypothesized that sense of ‘novelty’ of the stress may also contribute strongly to HPA 
responses during a PA (Abelson et al., 2007). Thus, understanding the hormonal responses 
during the initial uPAs is another major gap in the field.
4di. Autonomic and endocrine responses during natural PAs and ePAs
During a PA, the physical symptoms most often reported are related to cardiovascular, 
thermoregulatory, and gastrointestinal disturbances, as well as paresthesias. As discussed in 
section 2, amongst the self-reported somatic symptoms associated with PAs, heart-related 
symptoms are the most common during a PA [e.g., heart pounding 97%, tachycardia 86.1%, 
palpitations 78%] (Craske et al., 2010). However, as discussed in section 2, the few studies 
that used objective measures of ambulatory cardiovascular activity surrounding natural PAs 
show a lower incidence of events such as tachycardia that occur in ~38% (Barr Taylor et al., 
1982) to 58% (Taylor et al., 1986) of PAs. In the Magraf study, tachycardia did not occur in 
uPAs, but preceded ePAs (Margraf et al., 1987). Panic attacks clearly consist of physical 
symptoms associated with autonomic events. Yet, in some cases the autonomic response 
precedes the self-reported onset of the PA and arguably contributes to the PA, and/or occurs 
during the subjective experience of the PA (Margraf et al., 1987; Meuret et al., 2005). The 
majority of the physical symptoms are strongly associated with visceromotor or autonomic 
systems, which are comprised of the sympathetic and parasympathetic nervous system. 
However, the evidence for sympathetic and/or parasympathetic involvement in 
cardiovascular events during PAs (when present) are mixed, and in many instances the 
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specific results are not reproducible, which, as we will discuss, may reflect the complexity 
of the underlying causes of PAs (e.g,. genetic vulnerability and environment interactions).
There have been many studies that have objectively assessed autonomic responses by 
assessing cardiovascular and thermoregulatory activity in response to interoceptive or 
pharmacological challenges, but here we will review studies that assessed the sympathetic 
and parasympathetic activity using plasma assays prior to and during a PA, as well as 
utilizing accepted autonomic tests such as orthostatic tilt table tests and the Valsalva 
maneuver. The advantages of using standardized autonomic tests, such as postural 
orthostatic challenges, is that these are physiologically relevant, naturalistic, and fairly 
benign tests, compared to interoceptive or pharmacological challenges which can be 
stressful and assumes a priori that the stimuli or target is relevant to natural PAs. Some of 
the reviewed studies also assessed the stress hormone cortisol.
There have been few studies that have assessed neuroendocrine responses during naturally 
occurring PAs. A small study by Cameron and colleagues measured multiple plasma 
variables prior to and during 9 naturally occurring PAs (where one patient had one panic 
attack, two patients had two attacks each, and one patient had four attacks), and did not see 
any overall significant changes over time in norepinephrine, epinephrine, or norepinephrine 
metabolite MHPG, but there was also no significant change in heart rate or diastolic or 
systolic blood pressure. In individual assessments of cardiovascular activity during each PA, 
they noted high variability in data where heart rate increased in only 5 PAs, and blood 
pressure primarily rose during PAs, but decreased in others. They subjectively reported that 
norepinephrine consistently went up in 2 subjects during the 2 PAs they had, and was 
increased in another PA, but did not change in the others. There was a consistent lack of 
response of epinephrine in all cases. Cortisol appeared to increase in 7 PAs.
In order to get a more direct measure of sympathetic tone, direct nerve recordings of muscle 
sympathetic nerve activity in combination with plasma norepinephrine and epinephrine were 
done on 13 PD subjects and 14 healthy controls at baseline, and during a PA in 4 PD 
subjects (Wilkinson et al., 1998). They did not observe differences in sympathetic nerve 
activity, or total and cardiac plasma norepinephrine, and total epinephrine spillover rate at 
baseline, but did find increased anxiety symptoms in PD subjects prior to testing, as well as 
increased cardiac plasma epinephrine spillover. During the PA, the PD subject’s heart rate 
increased by 27%, and mean blood pressure also increased by 7.2%. Two of the four 
patients had large increases in sympathetic nerve activity during PAs, with no change in the 
two patients that has less intense PAs. During the 3 PAs where arterial plasma was collected, 
epinephrine total and spillover was respectively increased by ~35–67% and ~44–70% in all 
3 PD subjects following a PA. Norepinephrine total and spillover was respectively increased 
by ~5–7% and ~6–28% the 3 PD subjects following a PA.
The nature of the PA may also be relevant to the autonomic and endocrine response. In the 
previously discussed studies, it is not clear if the PAs assessed were completely uPAs or in 
some cases ePAs, but another study provoked ePAs in agoraphobic PD subjects by exposing 
them to agoraphobic situations. In this previously-mentioned Woods study in 1987, they 
exposed healthy and agoraphobic PD subjects to typical agoraphobic situations which 
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induced PAs in 13 out of 18 PD subjects, and no PAs in healthy subjects (Woods et al., 
1987). Assessments of autonomic and endocrine responses revealed that, post-exposure, 
both PD and healthy subjects had an increase in heart rate, but this response was greater in 
PD subjects. Although there was no difference in blood pressure responses post exposure in 
PD and healthy subjects, the PD subjects had higher systolic blood pressure at baseline and 
during pre-exposure. Exposing PD, but not healthy subjects to phobic situations increased 
cortisol, but the authors stated that there was only a trend for a between-subjects comparison 
and so concluded that the hypothalamic-pituitary-adrenal (HPA) axis response was not 
exacerbated in PD subject in agoraphobic situations. They also assessed norepinephrine 
activity by measuring MHPG, but did not see a baseline difference or a change post-
exposure.
4dii. Autonomic and endocrine responses in PD subjects during vasculomotor testing
A number of studies have examined orthostatic challenge with PD patients in an attempt to 
elucidate autonomic nervous system disturbances in this condition. This section is not meant 
to be a comprehensive meta-analysis of these findings, but rather highlight the 
inconsistencies in results and challenges in assessing autonomic and endocrine activity in 
PD. One common way of assessing the integrity of the autonomic nervous system (ANS) is 
through an orthostatic challenge, which employs a postural change from lying supine to 
being raised vertically (head-up). This can be done passively (motorized table) or by having 
the patient lie down and then stand on his/her own volition (after achieving a stable 
baseline). Continuous monitoring of blood pressure, heart rate, heart rate variability, and 
catecholamine levels permits a thorough assessment of the ANS, and other measures, such 
as anxiety instruments, can be used as well.
In a study of orthostatic challenge and the Valsalva maneuver, Weissman and colleagues 
compared 17 healthy control subjects to 20 patients experiencing PAs, and in pretesting 
determined that patients with PA had notably higher symptoms of anxiety. Following 20 
min of supine rest they found that there were no baseline differences in heart rate or resting 
blood pressure. However, patients with PD had greater increases in heart rate, mean blood 
pressure, and cardiac output index (product of the heart rate and mean arterial blood 
pressure), during each minute of quiet standing, and during the early phase of the Valsalva 
maneuver, which increases positive intrathoracic pressure stress (Weissman et al., 1987), 
which they conclude is suggestive of hyperactive sympathetic responses. They did not report 
if PAs occurred during the autonomic testing, but did make a note that they maintained a 
calm, quiet environment prior to and during testing. Yeragani and colleagues examined 30 
PD patients and 30 healthy controls, and after 10 min of supine rest found higher diastolic 
BP, higher HR responses to standing, and higher cardiac output in PD subjects (primarily 
female PD) (Yeragani et al., 1990). No patients experienced a PA during the study 
procedures. In a study by Stein and colleagues, 20 PD subjects and 20 age- and sex-matched 
healthy subjects performed voluntary orthostasis; they werereminded of benign nature of 
procedure and remained supine for 30 minbefore standing for 5 min with arms at their sides 
(Stein et al., 1992). Baseline anxiety symptoms were higher in PD subjects, but no 
difference in baseline HR or MAP was detected. However, PD subjects had a greater 
increase in HR in response to the orthostatic challenge. In a different subgroup, they did not 
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observe differences in sympathetic NE responses to postural change, but acknowledge that 
plasma norepinephrine levels may poorly reflect sympathetic activity (Folkow et al., 1983; 
Goldstein, 1983). Coupland and colleagues assessed BP and HR in 56 sex-matched PD 
subjects and 56 healthy controls, where they observed a higher dBP and sBP response in PD 
subjects when standing, but no difference in HR response, which they conclude supports an 
increase in sympathetic reactivity in PD subjects (Coupland et al., 2003). Stein & 
Asmundson noted that previous studies had not controlled for physical fitness, so they 
controlled for fitness, and examined 24 medication-free PD patients, of which 71% were 
agoraphobic, and 26 healthy controls in a number of autonomic challenges, including 
postural shift, isometric handgrip, Valsalva test, and cold pressor test (Stein and 
Asmundson, 1994). PD subjects did have increased anxiety symptoms, but failed to have 
differential cardiovascular responses to the autonomic tests. Plasma norepinephrine response 
also did not differ. However, the small subject numbers in some of these studies and the 
multiple comparisons being done make some of these findings insufficiently powered to test 
the validity of the differences or lack of effects noted by them.
Martinez and coworkers asked 30 PD subjects (18 with agoraphobia) and 10 healthy 
controls (age and sex matched) to rest supine for 10 min at which time they were tilted to a 
60 degree angle for 15 min, which is differs from voluntary standing procedures (Martinez 
et al., 2010). Ten min into the test, subjects were asked to control their breathing at a rate of 
15 breaths/min for 5 min to minimize the effects of breathing on HR and BP. At baseline 
they observed higher HR, lower HRV, and higher dBP in PD subjects whom also had 
increased anxiety symptom (not assessed in controls). PD symptom severity in the Panic 
Disorder Symptom Severity Instrument test was also associated with higher baseline HR. 
Unlike studies mentioned previously, the tilt procedure increased anxiety symptoms in the 
PD group, which was highest in the agoraphobic subgroup. The tilt procedure also increased 
HR higher in the PD group. Additionally, the tilt procedure induced PAs in 23% of PD 
patients and no controls. Symptoms reported included ~75–85% reporting feeling faint and 
short of breath, and ~50% feeling afraid. Controlled breathing produced higher HR 
responses in the PD group.
The contradictory data in the previously mentioned studies could be due to many of the PD 
subjects that were assessed having been diagnosed with PD for 5–8 years. In an effort to 
assess autonomic tone closer to the diagnosis of PD, Ito and colleagues analyzed autonomic 
activity during a tilt table test among 8 newly diagnosed medication free, age-, and sex-
matched PD patients with a 6.6 month mean duration of illness and ~11 PAs/month, whom 
they compared to 13 age- and sex-matched healthy controls (Ito et al., 1999). Subjects were 
all of the same physical fitness. Following >30 min of supine rest and with controlled 
breathing of 15 breaths/min, the motorized table was tilted to 70˚ for 5 min which did not 
induce a PA in any subject. There were no differences in HR or HRV at baseline, nor was 
there a difference in HR response to tilt. However, during the tilt, HRV analyses revealed 
that low frequency and high frequency were both higher in PD subjects (suggestive of 
increases in sympathetic and parasympathetic tone), but there was no difference in overall 
sympathovagal balance (low frequency and high frequency ratio). Additionally, although PD 
subjects had increased anxiety symptoms none of these symptoms correlated with 
physiological variables. Their results suggest that, at least in early stages of PD, co-
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activation of both branches of the autonomic nervous system may be occurring, which may 
differ from ANS differences observed in panic patients with more severe/longer courses of 
illness.
4diii. Concluding remarks on autonomic and endocrine responses in PD
Collectively, the results of these studies are mixed, with some showing no differences in 
autonomic activity at baseline or during challenges, but more do observe some evidence of 
parasympathetic withdrawal, sympathetic hyperactivity, or a combination of the two at 
baseline and more evidence of disruption during autonomic testing. The inconsistencies in 
these results are not surprising given the complications associated with PD which are 
difficult to control for (e.g, duration of illness, sex and age, physical fitness, previous and 
current medications, and comorbidities). PD subjects have a fairly consistent increase in 
baseline anxiety compared to healthy subjects that can also impact the testing, and there are 
limitations in certain autonomic assessments such as using plasma norepinephrine as a 
indices of sympathetic activity.
Given the heterogeneity of the physical symptoms that occur during a the majority of 
documented PAs associated with the PD diagnosis, and the variability in the timing of 
objective measures associated with the physical symptoms, it is unlikely that the etiology of 
PAs is associated with a direct disturbance in the peripheral nervous system. Yet, some 
conditions associated with clear autonomic disruptions are associated with an increase in the 
prevalence of PAs and PD. For instance, the incidence of PAs and PD was assessed in 
normotensive and hypertensive age- and gender-matched patients from one primary care 
practice. Prevalence of PAs during the last 6 months and in a patient’s lifetime was 
respectively ~11% and ~22% for normotensive patients and ~18% and ~35% for 
hypertensive patients, which was significantly higher (Davies et al., 1999). Diagnosis of PD 
was ~7% in normotensive patients and ~12.5% in hypertensive patients. It is not clear if the 
autonomic disruption led to the PAs and PD, since half the hypertensive patients recalled 
that the diagnosis of hypertension preceded PA while the other half said the PAs preceded or 
coincided with the hypertension. The hypertensive patients also had higher anxiety 
symptoms which may or may not have been present prior to the hypertension. Many of the 
studies discussed here assessed sympathetic activity in PD and during PAs with plasma 
assays for norepinephrine and epinephrine, which should be interpreted with caution. The 
hypertension condition is a persistent increase in blood pressure that is typically associated 
with increased plasma norepinephrine, which suggests that there is a hyperactive 
sympathetic nervous system (Goldstein et al., 1983). Yet this is controversial, as is the 
accuracy of plasma norepinephrine assays in assessing sympathetic activity since most of 
norepinephrine’s effects on target tissues is from postganglionic terminal release at specific 
targets (Folkow et al., 1983; Goldstein, 1983).
As mentioned in section 2, results from objective measures of cardiovascular activity 
preceding and during a PA vary, with events such as tachycardia occurring prior to or during 
the PA, or not at all. In 1986, Clark and colleagues hypothesized that PAs are a catastrophic 
cognitive misinterpretation of bodily sensations that could include cardiovascular events 
(Clark, 1986). Some supportive evidence for this comes from a study in 1990, where Balon 
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and colleagues i.v. administered 20µg of the non-selective β-adrenergic agonist isoproterenol 
to 78 PD subjects and 45 healthy controls which induced PAs in 54 (69%) PD subjects and 
no controls (Balon et al., 1990). In patients that panicked to isoproterenol, shortness of 
breath and fear of going crazy were significantly increased compared to non-panicking 
patients. In the non-panicking PD group there were more significant reports of fear, 
pounding heart, and light headedness, and trembling compared to controls. Interestingly, 
females were more represented among panicking patients, but the study was not sufficiently 
designed to test for any cognitive patterns that were sex-specific. As the authors state, it is 
possible that an additional, non-cognitive component may account for some of the 
symptoms elicited by isoproterenol, so caution should be taken in this study’s 
interepretation, as the infusion rate was significantly different for panicking patients 
compared to the other groups.
Overall, for the majority of documented PAs associated with the PD diagnosis, the 
conflicting data on an underlying disruption of autonomic and endocrine tone presented in 
this section only further supports the complexity and heterogeneity of the physical 
symptoms associated with PAs. Overall, autonomic disturbances are clearly associated with 
PAs, but the diverse interactions between genes, environment, development, and 
comorbidities may lead to unique presentations of cognitive and physical symptoms. In the 
subsequent section discussing neural circuits associated with PD and PA vulnerability, an 
ongoing question is whether or not physical symptoms associated with autonomic disruption 
in PAs can be attributed to pathology associated with one or more of the following: 1) 
disruption of critical autonomic regulating brainstem regions and/or peripheral nervous 
system; 2) disruption at panic-generating brain regions such as the PeF, DPAG or amygdala; 
or 3) loss of cortical inhibition of panic-generating brain regions and brainstem regions 
involved in autonomic regulation. In defense of the latter explanation, there is evidence that 
an interplay between genes, environment and development may lead to loss of medial 
prefrontal cortical inhibition of panic-generating brain regions (e.g, PeF, DPAG, and/or 
amygdala) resulting in hyper-reactivity of panic-generating brain regions to visceral 
interoceptive signals being routed through the insula, and may lead to subsequent over-
generalization of fear reactions to aversive signals. This can lead to anticipatory anxiety and 
ePAs, as well as avoidance of situations associated with previous PAs (i.e, agoraphobia).
Section 5 – Neural Circuits Implicated in Adaptive Panic, and Recurrent 
Pathological PAs in PD
5a. Neural circuits implicated in PAs in PD
Currently, the neuroanatomical circuits underlying the initial vulnerability to PAs or even 
subsequent repeated PAs in humans are poorly understood. A recent meta-analysis by 
Dresler and colleagues assessed structural (computed tomography, CT; and magnetic 
resonance imaging, MRI; Voxel-based morphometry, VBM) and functional (functional 
MRI; and near infrared spectroscopy) imaging studies in PD subjects (Dresler et al., 2013). 
In this meta-analysis they acknowledged that functional imaging studies in particular are 
inherently difficult when studying anxiety disorders such as PD due to previous 
pharmacological or psychological treatments, and higher baseline anxiety which in many 
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cases leads to altered respiration. This alteration may cause hypo or hypercapnia, which 
induced vasoconstriction or vasodilation, respectively, of blood vessels, which confounds 
imaging methodologies dependent on cerebral blood flow. These approaches also require the 
subject to be in a small, confined area where a rapid escape would be difficult, which is a 
situation associated with agoraphobia and a common trigger of ePAs. As discussed in detail 
in section 6 and 7, another hurdle is that many panicogenic brain regions and neurochemical 
systems implicated in PAs in humans and adaptive panic responses in rodents are located in 
small nuclei in structures such as the hypothalamus and brainstem, and the high 
vascularization of the former makes these areas difficult to assess. Even less is known about 
brain activity during naturally-occurring PAs which are hard to assess due to their 
unpredictable onset in many cases. Although caution should be taken in interpreting the 
results, functional brain activity has been assessed at baseline, during naturally occurring 
PAs (a few case studies), and following panicogenic stimuli (e.g., CO2, NaLac, or 
pharmacological challenges discussed in section 6) and do provide insight into brain regions 
showing hypo and hyperactivity in PD subjects. In the subsequent sections we will discuss 
evidence for structural and functional imaging abnormalities in PD subjects.
5bi. Prefrontal cortex: evidence of hypoactivity in PD patients
Dresler and colleague initially assessed evidence for structural abnormalities and 
summarized that PD subjects had fairly consistent reduced volumes in the temporal lobe 
(Asami et al., 2009; Lai et al., 2010; Sobanski et al., 2010), and limbic structures such as the 
amygdala (Massana et al., 2003; Hayano et al., 2009; Lai et al., 2010), but also in frontal 
cortical areas (Protopopescu et al., 2006; Asami et al., 2009; Lai et al., 2010). In functional 
imaging studies, resting state findings in PD have very mixed results (Dresler et al., 2013). 
In one study, regional Cerebral Blood Flow (rCBF) in frontal cortical areas was generally 
lower in the 22 medication-free PD subjects compared to 19 healthy controls (Eren et al., 
2003). However, respiration and pCO2 levels were not controlled for, and the differences 
could be due to such global cerebral blood flow changes. Another resting state study noted 
that, compared to 22 healthy controls, 12 medication-free PD subjects with higher baseline 
anxiety had increased glucose uptake in the bilateral amygdala and brainstem indicating 
hyperactivity that could be a result of loss of frontal cortical inhibition (Sakai et al., 2005). 
The reduced volumes in frontal cortical regions could be related to aberrant cortical growth 
and remodeling that occurs during adolescence (see section 3b, and Figure 2b), which could 
lead to blunted frontal cortical inhibition of fear and panic-generating sites such as the 
amygdala, perifornical hypothalamus, and dorsal periaqueductal gray (discussed in 
subsequent sections). Another consideration is that during adolescence a negative 
synchronization between the mPFC and amygdala occurs; early life stress appear to 
accelerate this synchronization; and the efficiency of this negative synchronization is 
associated with reduced anxiety (Gee et al., 2013a). The consequences of hypoactivity in the 
prefrontal cortex may also explain the tendency of patients with PD to misinterpret bodily 
sensations as being dangerous or catastrophic during or preceding a PA and have disrupted 
perception of control that can predispose them to ePAs and agoraphobia [see review (Austin 
and Richards, 2001)]. In a meta-analysis by Bar-Haim and colleagues they found that, 
compared to healthy controls, patients with anxiety disorders (including PD) generally tend 
to interpret non-threatening cues as threatening (Bar-Haim et al., 2007). Yet it is important 
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to note that presence of catastrophic cognitions (e.g., catastrophic fear of dying and/or losing 
control) is not critical for a diagnosis of PD, and these 2 cognitive symptoms are heavily 
outweighed by the 11 physical symptoms for a diagnosis of PD, which requires 4 of the total 
13 symptoms be present. This may explain why studies that have assessed attentional and 
interpretational biases in PD patient (some of which could qualify as having no fear PAs or 
no agoraphobia) have had inconsistent results (McNally et al., 1990; McNally and Lukach, 
1992; McNally et al., 1992; McNally et al., 1994; Lundh et al., 1999; De Cort et al., 2008). 
Regardless, there is evidence that catastrophic misinterpretations of bodily sensation and 
disrupted perception of control can predict PA severity in patients with PD (159 included in 
study) with or without comorbid agoraphobia (Casey et al., 2004).
Although the amygdala has been shown to be critical for acquisition of fear memories 
following a traumatic experience, there is evidence that the mPFC plays a critical role in 
developing coping strategies, and in safety learning (e.g., extinction of fear and retention of 
extinction) following traumatic experiences that have occurred previously, but that are no 
longer a threat. For instance, humans with focal lesions of the amygdala (Bechara et al., 
1995; LaBar et al., 1995) have impaired acquisition of fear, and fMRI studies have shown 
that amygdala activity increases during acquisition of fear (Knight et al., 2005), but mPFC 
activity increases during extinction of fear (Phelps et al., 2004). Furthermore, mPFC 
thickness is positively correlated with sustained extinction (Milad et al., 2005; Rauch et al., 
2005). Overall, this is further support that reduced mPFC activity that is associated with PD 
could contribute to ePAs, and agoraphobia, but other evidence also suggests reduced mPFC 
activity could also lead to poor coping strategies. In 2008, Goldin and colleagues showed 
that exposing women to aversive films (compared to neutral films) increased negative 
responses and enhanced mPFC, insula and amygdala activity. However, during reappraisal 
of the negative experience their negative reaction was reduced, which was associated with 
enhanced mPFC activity, and decreased insula and amygdala activity (Goldin et al., 2008). 
An important aspect of reappraisal of a negative experience is determining optimal coping 
strategies, and the ability to control fear responses. Reappraisal is also a critical component 
of CBTs which are discussed in the following section and if reappraisal methods enhance 
mPFC activity this could explain the efficacy of CBTs in treating PD and agoraphobia.
5bii. Prefrontal cortex: potential site of efficacy for CBT & rTMS in treating PAs
Although psychological therapies such as cognitive behavioral therapy (CBT) are 
considered the gold standard for treating anxiety disorders, the efficacy of psychological 
therapies in randomized control trials and effectiveness in real life situation is dependent on 
several important factors. Specifically, psychological therapies that include CBT, exposure 
therapy (ET), and relaxation breathing therapies (RBT) have differing results depending on 
the type of anxiety disorder; the type of psychological therapies used; and if this 
psychological therapy is used in combination with an additional psychological therapy or in 
combination with pharmacotherapy (Mitte, 2005; Ost, 2008; Sanchez-Meca et al., 2010; 
Otte, 2011; Hofmann et al., 2012b; Hofmann et al., 2012a). In regards to the efficacy of 
psychological therapies on different anxiety disorders, CBT is efficacious in treating PD, but 
is more efficacious in patients with acute stress disorder or PTSD (Otte, 2011). The type of 
psychological therapy is also important, as is the combination of them for treating anxiety 
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disorders. In 2010, Sanchez-Meca and colleagues conducted a meta-analysis of 65 studies to 
determine the efficacy and usage of different psychological therapies and combinations of 
those therapies for treating PD and agoraphobia. This meta-analysis revealed that exposure 
therapy (ET) was most widely used (55/65 studies with in vivo exposure being most 
prevalent), following by cognitive behavioral therapy (CBT) (46/65 studies), and relaxation 
breathing therapies (RBT) (30/65 studies) and in some studies these were done in 
combination with eachother. For panic symptoms, the most efficacious treatment was a 
combination of ET+RBT, followed by ET alone or in combination with the other therapies. 
For agoraphobia symptoms, no single methods was effective, only combinations of these 
therapies were effective with CBT+RBT’s being most effective and other combinations 
being equivalently effective. Others have compared the efficacy of psychological therapy to 
pharmacotherapy, and have determined that psychological therapies such as CBT were at 
least as effective as pharamacotherapies such as TCAs, SSRIs, and benzodiazepines (Mitte, 
2005), and there is evidence that the combination of the psychological therapies and 
pharmacotherapy may be even more efficacious (Hofmann et al., 2009; Otto et al., 2010; 
Hofmann et al., 2012a). Although psychological therapies engage multiple exteroceptive 
sensory brain regions sites such as the primary visual cortex, there is evidence that the 
mPFC may be a critical relay site for efficacy of psychological therapies. One PET study 
that assessed glucose utilization in PD patients prior to and after successful reductions of 
panic symptoms post CBT found enhanced activity in the mPFC and decreased activity in 
the limbic system and brainstem (Sakai et al., 2006). Another study using PET to assess 
glucose utilization post CBT saw similar increases in PFC activity (Prasko et al., 2004).
5c. Insula as a critical site for sensing and relaying interoceptive cues
Functional imaging preceding and during a PA is limited to a few case studies that have 
complicated comorbid diagnoses and, in some cases, were not medication-free. However, 
the imaging that has been done does provide potential insight into neural circuits relevant to 
PAs. In one case study, a PA occurred in a subject with specific phobia during the fMRI 
after they saw a sad face and worried about what they may see next (Dresler et al., 2011). 
The subject aborted the fMRI once the PA occurred, but an analysis done on the data 
gathered up to the PA revealed significant increases in activity in the insula that was 
associated with feelings of discomfort then a subsequent increase in activity in the right 
amygdala just prior to the PA and discontinuation of the fMRI. In another case study, a 
female subject with PD treated with escitalopram and CBT was free of apparent anxiety 
prior to fMRI, but during the fMRI began to develop PA symptoms (i.e., anxiety, sweating, 
tremor, difficulty breathing, as well as objectively measured tachycardia) followed by more 
intense hot flashes, dizziness, and palpitations which lasted for ~3–5 min (Pfleiderer et al., 
2007). In this case, an increase in activity was observed in the left insula during the initial 
onset of anxiety, followed by increased activity in the right amygdala during the PA. There 
are also functional studies of PD where a panicogenic challenge was administered. In studies 
using NaLac, there does appear to be a fairly consistent increase in glucose metabolism and 
rCBF in the insula in most cases [(Reiman et al., 1989; Dager et al., 1994; Dager et al., 
1997) and no effect in other cases (Layton et al., 2001)], and also with a surprising lack of 
effect within the amygdala and temporal lobe in these studies. As reviewed by Dresler and 
colleagues, and Shin and Liberzon, panicogenic stimuli such as NaLac, and hyperventilation 
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do tend to increase activity in the insula but do not alter activity within the amygdala [see 
reviews by (Shin and Liberzon, 2010; Dresler et al., 2013).
The significance of insula activation prior to a PA, or following interoceptive challenges, 
and its activity correlating with feeling queasy and uncomfortable prior to a PA (Dresler et 
al., 2011) is that the insula is hypothesized to be the primary viscerosensory or interoceptive 
relay center in the brain [see Figure 2, and review (Palkovits, 2010)]. This ongoing 
hypothesis is based on the insula’s high responsivity to a variety of interoceptive cues, such 
as restricted breathing (von Leupoldt et al., 2008), bladder distension (Matsuura et al., 
2002), and temperature changes (Craig et al., 2000). In a fMRI study, Critchley and 
colleagues found that increased activity in the right anterior insula predicted the subject’s 
accuracy for detecting his/her heartbeat, which was used to assess visceral awareness 
(Critchley et al., 2004). Thus, viscerosensory-related stimuli, such as a change in arterial 
PCO2 levels or a change in cardiovascular activity, would most likely be routed through the 
insula, where the signal is passed on to emotional and autonomic centers, which collectively 
produce an awareness of physical symptoms associated with PAs such as feeling short of 
breath or a pounding or racing heart. The perception of these events can vary greatly 
depending on the emotional and physical state of the person. A feeling of breathlessness or a 
strong change in cardiovascular activity during exercise would be perceived as normal, but 
in other situations these sensations may be perceived as abnormal, and interpreted as 
something being wrong with the body’s internal state. Spiegelhalder and colleagues have 
argued that the relevance of the insula activity increasing prior to a PA, is to act as an 
“internal alarm” to relay potentially life-threatening interoceptive stimuli to emotional and 
autonomic brain regions (Spiegelhalder et al., 2009), which, depending on the emotional 
state of the person, could produce a variety of emotional reactions. Subjects with PD may be 
predisposed to perceiving interoceptive stimuli as being negative or aversive since baseline 
levels of anxiety are higher in PD subjects. Further discussion of the significance of the 
insula and connections to panic-generating brain regions will be made in section 7, where 
animal research related to panic is discussed.
5d. The amygdala’s role in uPAs and ePAs
As discussed in sections 5a–b, following spontaneous PAs and laboratory induced PAs using 
CO2 or NaLac, there is an inconsistent increase in activity in the amygdala surrounding the 
PA event. This is surprising since the amygdala has been shown to play a critical role in 
learning and memory associated with fearful events in humans, and has been extensively 
characterized in preclinical rodent studies which are discussed in section 7. For instance, 
subjects with bilateral calcification/atrophy of the amygdala (due to a rare genetic condition 
called Urbach-Wiethe disease) have impaired recognition and recall of fearful faces 
(Adolphs et al., 1994; Adolphs et al., 1995)(see Figure 3). Deep brain stimulation of the 
amygdala region leads to a variety of emotional symptoms that are aversive in some cases 
(e.g., fear, depression, anger), but can also be associated with positive emotional states (e.g,. 
euphoria and laughter) (Penfield, 1952; Chapman et al., 1957; Van Buren, 1961). In some 
instances, these studies also observed physical symptoms associated with PAs such as 
pounding heart, and hot flashes and sweating. Additionally, some subjects reported 
remembering past events with emotional valence. In a more recent study, Meletti and 
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colleagues determined that deep brain stimulation of the medial temporal lobe in 74 subjects 
tested on 79 emotional responses, 85% were associated with fear, 11% were pleasant, and 
4% elicited a sad response (Meletti et al., 2006). They also noted that fear responses in 
women were more common than men. In light of the amygdala’s role in emotional 
responses, Feinstein and colleagues hypothesized that subjects with Urbach-Weithe disease 
would have reduced panic symptoms following exposure to inhalation of 35% CO2 
(Feinstein et al., 2013). Surprisingly, the CO2-evoked fearalso induced symptoms associated 
with PAs in the three patients with bilateral amygdala damage. In this particular study, an 
aversive interoceptive stimuli associated with suffocation did not require an intact amygdala 
to elicit strong fear and panic symptoms. Another case study also noted that an intact 
amygdala was not necessary for a subject to experience PAs (Wiest et al., 2006). Thus, in 
the instance that an interoceptive trigger is the cause of a PA, the amygdala activity may not 
increase or be involved in the PA. Yet, it is interesting that while healthy control subjects 
experienced significant anticipatory anxiety prior to a subsequent CO2 inhalation, the 
subjects with bilateral amygdala damage did not, which demonstrates that the amygdala 
does appear to be important for anticipatory anxiety responses when in previously aversive 
situations. This suggests that the amygdala may be very important for ePAs, when the PD 
subject is in an agoraphobic situation. Overall, the amygdala’s involvement in PAs may 
differ depending on baseline anxiety states, situations in which PAs occur, and the nature of 
the trigger (i.e., exteroceptive versus interoceptive, or a combination).
5e. Perifornical hypothalamus and dorsal periaqueductal gray as the putative sites for PAs
So if the amygdala is not the locus of uPAs, what is a likely candidate for such panic-
generating site? There are striking similarities between cognitive and physical symptoms 
associated with PA and those resulting from deep brain stimulation of subcortical nuclei in 
the perifornical hypothalamus (PeF) and the dorsal column of the periaqueductal grey 
(DPAG) (see Figure 3). For instance, deep brain stimulation of the perifornical area in the 
posterior hypothalamus (PeF) of humans produces cognitive fear symptoms such as self-
reported panic and fear of dying, as well as physical symptoms, such as tachycardia, 
increased blood pressure, and hyperventilation (Rasche et al., 2006; Wilent et al., 2010). In 
another deep brain stimulation study, stimulating the posterior hypothalamus around the 
fornix (perifornical) led to increased feelings of anxiety, thermal sensations, and paresthesias 
(Wilent et al., 2011). Similarly, deep brain stimulation of the DPAG, but not its ventral 
column, elicited cognitive fear symptoms such as feeling of panic, intense anxiety, or 
fearing imminent death that were accompanied by physical symptoms such as chest pain, 
tachycardia, dyspnea, and thermal sensations (Nashold et al., 1969; Young, 1989). As 
further discussed in section 7, rodent studies have identified that these structures play a 
critical role as primary visceromotor systems, as well as playing a critical role in fight or 
flight responses to imminent threats. Rodent studies in Section 7 also provides further 
evidence for the PeF and DPAG in regulating normal and potentially pathological panic 
responses (e.g., panic responses following local stimulation; their responsiveness to 
panicogenic stimuli such as CO2 and NaLac; and connections to brain regions implicated in 
panic attacks and panic response).
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Overall, based on an extensive review of the current and somewhat complicated literature, 
we would posit our hypothesis (detailed further in section 7) that a combination of genetic, 
developmental, hormonal, and environmental factors leads to a reduction in ventromedial 
prefrontal cortical (vmPFC) inhibition of panic generating lower brain regions, underlies the 
initial ‘spontaneous’ uPAs. This pathology could be further compounded by the 
development of hypersensitivity of insula network for interoceptive cues resulting in 
recurrent PAs. This repeated activation of the panic-generating subcortical sites, with 
subsequent recruitment and plasticity within the extended amygdala fear-hippocampus-
cortical circuits, leads to a vulnerability to developing situational ePAs and agoraphobia. 
Evidence for loss of vmPFC control of panic-generating site is based on the previously 
mentioned morphological imaging studies showing reduced volumes in frontal cortical areas 
(Protopopescu et al., 2006; Asami et al., 2009; Lai et al., 2010), which could lead to blunted 
cortical inhibition of fear and panic generating sites. Thus, more subtle interoceptive sensory 
input to the insula that is relayed to panic-generating sites may elicit a stronger response of 
that region if vmPFC inhibition of that region is compromised, which could trigger a false 
“alarm”. Cognitive behavioral therapy (CBT) has been shown to enhance mPFC activity in 
subjects with anxiety disorders, which may explain why CBT is effective in treating PAs 
and PD.
Section 6: Neurochemical Systems Implicated in PD: Genes, Triggers and 
Treatments
6a. Heritability and genes associated with PD and PA presentation
As discussed in section 3a, the prevalence of PD in first degree relatives (~11%) and 
monozygotic twins (30–40%) of PD subjects, compared to 2–5% in general population, is 
fairly strong evidence that genetic background is an important contributing factor to PD 
etiology [see meta-analyses and reviews by (Hettema et al., 2001; Schumacher et al., 2011)]. 
Yet, as mentioned in section 3a, although a recent meta-analysis of linkage and candidate 
gene association studies concluded most studies produced inconsistent results, it did observe 
some promising replicable chromosomal locations, and specific candidate genes (Maron et 
al., 2010). As discussed by Maron, the advantage of linkage analyses is the ability to 
perform an unbiased comprehensive genomic search of genes and alleles that may be 
associated with PD and PAs. The disadvantage is the relative inability to detect and locate 
specific genes associated with a condition. Conversely, candidate gene studies are 
hypothetically driven, but are restricted to screening specific genes. It is beyond the scope of 
this review to discuss all the chromosomal locations and candidate genes associated with 
PAs and PD.
A number of neurochemical hypothesis are also proposed for the etiology of panic disorder, 
primarily based on the pharmacological therapies that work in treating PAs and PD. For 
example, symptoms associated with PAs in PD, and laboratory-induced PAs can be rapidly 
treated with benzodiazepines (Charney and Heninger, 1985; Tesar and Rosenbaum, 1986; 
Ballenger et al., 1988) which effectively enhance inhibitory GABAergic tone. Panic attacks 
associated with PD can also be treated with slower-acting pharmacological therapies that 
enhance monoaminergic (e.g., serotonin, norepinephrine, epinephrine, dopamine, and 
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histamine) activity globally [using tricyclic antidepressants (Rifkin et al., 1981) or 
monoamine oxidase inhibitors (MAOI) (Kelly et al., 1971)], or by specifically targeting 
serotonergic or noradrenergic systems with reuptake inhibitors [see review (Cloos and 
Ferreira, 2009)]. Here, we will focus the discussion on major neurochemical systems 
implicated in PAs and PD by linkage analyses and candidate gene studies, and how some of 
these systems are current targets for treating and eliciting PAs.
6b. GABAergic system
GABA is a major inhibitory neurotransmitter that is synthesized and released throughout the 
brain, and the panic-generating PeF and DPAG regions are tonically inhibited by GABA. 
GABA is also heavily implicated in PAs and PD, and most evidence suggests that there is 
reduced inhibitory GABAergic tone in patients with Panic Disorder. For instance, patients 
with Panic Disorder have reduced GABAAR binding in the frontal cortex (Nikolaus et al., 
2010), and panic patients demonstrate deficits in central GABA concentrations (Goddard et 
al., 2001b). There is evidence of linkage of PD to region 2q37, as well as other suggestive 
regional linkages on chromosome 2 (Fyer et al., 2006). The glutamate acid decarboxylase 1 
(GAD1) gene which produces the GAD67 enzyme responsible for GABA synthesis, which 
is located on 2q31.1 has been shown to be associated with PD (Hettema et al., 2005). The 
effects of loss of central GABAergic tone can be observed in a study where the drug 
FG-7142, which mostly disenhances GABAergic tone, by acting as an inverse 
benzodiazepine agonist at most GABAA receptors, was shown to induce severe anxiety in 
humans (Dorow et al., 1983). Collectively, these data most likely explain why 
benzodiazepines, which enhance GABA activity, are effective at treating panic symptoms 
(Nutt et al., 2002; Baldwin et al., 2005; Bandelow et al., 2008; Cloos and Ferreira, 2009). 
Yet, although benzodiazepines represent a fast-acting panicolytic treatment, routine usage 
makes the drug less effective due to desensitization, and there are many side effects and 
safety concerns such as sedation and addiction. Furthermore, withdrawal from the 
benzodiazepine alprazolam leads to rebound PAs and symptoms such as weakness, 
insomnia, tachycardia, lightheadedness, and dizziness in 15/17 PD subjects (Fyer et al., 
1987), which make this treatment mechanism a short term option and a second-line 
approach to treating PAs and PD. It is interesting to note that in the de Beurs study 
mentioned in section 2, there were no differences in the number of PAs in PD subjects that 
were using benzodiazepines and not, but they did report less nocturnal PAs and less severe 
PA symptoms (de Beurs et al., 1994).
6c. Serotonergic and noradrenergic systems
Some of the first evidence for involvement of serotonin and noradrenergic involvement in 
anxiety and PD pathology was due to the effectiveness of tricyclic antidepressants (TCA), 
such as imipramine and clonipramine, for managing symptoms in these disorders [see meta-
analyses (Bakker et al., 2002; Perna et al., 2011)]. Although TCAs have pharmacological 
actions at many receptors, they primarily act as serotonin and norepinephrine reuptake 
inhibitors at the serotonin and norepinephrine transporters (5-HTT, and NET, respectively) 
with low affinity for dopamine transporters, which increases synaptic concentration of the 
neurotransmitters to enhance neurotransmission. Other lines of evidence came from 
pharmacological inhibition of monoamine catabolism using monoamine oxidase inhibitors 
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(MAOIs) such as phenelzine for the treatment of PAs and PD, but this is considered a third- 
or fourth-line approach since it requires a tyramine-restricted diet, and can produce serious 
side effects such as hypertensive crisis.
Selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors 
(SNRIs) are also effective treatments for PAs and PD, and the safety and efficacy of these 
compounds will be discussed in the subsequent sections. It is important to note that unlike 
benzodiazepines, these are not fast-acting panicolytic compounds. In some cases, TCAs (and 
also SSRIs and NRIs) increase anxiety initially, and begin to show anxiolytic and 
panicolytic properties after 2–3 weeks of daily treatments. Thus the mechanism by which 
these compounds are panicolytic are through compensatory changes that occur with repeated 
use, and a therapeutic option is to initially co-administer a low dose of a benzodiazepine 
with SSRIs to PD patients, which has been shown to result in a 41% response rate, 
compared to 4% response rate for placebo + SSRI group in the first week of treatment 
(Goddard et al., 2001a).
Currently SSRIs and NRIs represent the first-line treatment for PAs and PD due to their 
similar efficacy in treating PAs (Pollack et al., 2007a; Pollack et al., 2007b), with some 
evidence that SSRIs are more tolerable and safe. There are several FDA-approved SSRIs for 
treating Pas, including fluoxetine, paroxetine, and sertraline, and NRIs such as venlaflaxine. 
In regards to efficacy, TCAs are arguably as effective as SSRIs and NRIs, but they are 
considered a second-line approach for treating PAs and PD due to side effects and 
tolerability. Bakker’s meta-analysis comparing the efficacy of TCAs and SSRIs in treating 
PAs, found that TCAs and SSRIs were comparable in their efficacy (respectively 60% and 
55% of PD patients PA free), but the dropout rate was ~33% for TCAs, and ~18% for 
SSRIs. The efficacy for SSRIs and NRIs was also similar, PD patients reported significantly 
less PA symptoms at 61% for paroxetine, 55–60% for venlaflaxine, and 35% for placebo 
(Pollack et al., 2007b). Thus, regardless of tolerability and safety issues, targeting 
serotonergic and/or noradrenergic systems pharmacologically is clearly effective in treating 
PAs in PD.
Similarly, PAs can be induced in the laboratory with serotonergic and noradrenergic 
pharmacological agents. For instance, serotonin-enhancing drugs such as the trazadone 
metabolite meta-chlorophenylpiperazine (mCPP, which is an agonist at most serotonin 
receptors, inhibits reuptake, and enhances release of serotonin) elicits PAs at a higher rate in 
PD subjects (12/23, 52%) that healthy controls (6/19, 32%) following 0.1 mg/kg i.v. 
infusions (Charney et al., 1987a). The indirect serotonergic agonist fenfluramine when given 
orally at 60mg, increases anxiety symptoms in 9/9 PD subjects, but not significant anxiety 
symptoms in the 9 healthy controls (Targum, 1992). An earlier study by the same group 
showed PA frequency increased response rate to 60 mg oral fenfluramine which induced PA 
symptoms in 9/12 patients (75%) whom had a high incidence of PAs (≥1 PA/week), and 
0/14 PD patients with ≤ 1PA/month (Targum, 1991). Yohimbine, which enhances 
noradrenergic activity by blocking presynaptic α2 adrenergic autoregulation also induces 
PAs at a higher rate in PD subjects than healthy controls. In one study, yohimbine (4 oral 
capsules of 5mg) produced PAs in 37/68 (54%) of PD subjects with agoraphobia, compared 
to 1/20 healthy controls (5%) (Charney et al., 1987b). Collectively, these pharmacological 
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studies provide compelling evidence that serotonergic and noradrenergic system 
hyperactivity may contribute to PAs, and that PAs can be effectively treated by targeting 
either or both systems.
There is also evidence from candidate gene studies that polymorphisms of serotonergic and 
noradrenergic proteins may contribute to PAs and/or severity of PAs. For serotonergic 
systems, there have been multiple candidate genes associated with PD or severity of PAs. 
These include the serotonin transporter, (5-HTT) and the serotonin 2A receptor (HRT2A) 
(Maron et al., 2005; Maron et al., 2010). Of the two candidates, the polymorphism of the 5-
HTT gene has gained a lot of attention in regards to anxiety disorders and, more recently, 
PD. Humans carry a polymorphism in the promoter region of the serotonin transporter (5-
HTT) gene, where the dominant short (s) allelic variant reduces transcriptional efficiency of 
the 5-HTT (Lesch et al., 1996), which is evidenced by reduced brain 5-HTT mRNA levels 
(Little et al., 1998), and reduced 5-HTT binding sites (Heils et al., 1996). Lesch and 
colleagues also observed that humans with the polymorphism associated with reduced 5-
HTT transcription had increased anxiety-associated traits. Specifically in regards to PAs and 
PD, the 5-HTT s-allele polymorphism has not been shown to be associated with increased 
incidence of PAs, but has been shown to be strongly associated with the severity of panic 
symptoms (Lonsdorf et al., 2009). Surprisingly, Schruers and colleagues determined that 
healthy humans with the 5-HTT s-allele polymorphism displayed less fear to the 
panicogenic interoceptive stimuli CO2 (Schruers et al., 2011). Yet, other clinical studies 
have shown that humans with this polymorphism have enhanced reactivity of the amygdala 
(Hariri et al., 2002; Heinz et al., 2007), and better acquisition of fear conditioning 
(Garpenstrand et al., 2001) than those with only long alleles. Klumpers and colleagues also 
determined that humans carrying at least one short allele for the 5-HTTLPR polymorphism 
(S/S or S/L) showed stronger fear-potentiated startle compared to long allele (L/L) 
homozygotes, but did not show a deficit in the extinction of the fear after the offset of threat, 
and hypothesized that the variation in 5-HTT function affects the magnitude of an 
unconditioned defensive reaction, but not the capacity for fear regulation (Klumpers et al., 
2012). Given Schruers’ data and that the amygdala is not critical for some CO2-induced PAs 
(Feinstein et al., 2013), the 5-HTT s-allele polymorphism may not predispose PD subjects to 
some interoceptive induced PAs. However, the amygdala hyperactivity associated with the 
5-HTT s-allele polymorphism may predispose PD patients to agoraphobia and ePAs. This 
polymorphism may also explain why SSRIs are not effective in treating PAs in some PD 
subjects.
Candidate gene studies have also identified noradrenergic proteins that are associated with 
PD. Among these, a candidate gene that is more consistently associated with PD is catechol-
O-methyltransferase (COMT) which maps to 22q11.21, and is involved in the inactivating/
degrading the catecholaminergic neurotransmitters epinephrine, norepinephrine, and 
dopamine; the first two are implicated in normal and pathological panic (Maron et al., 2010). 
The specific effect of this polymorphism of COMT associated with PD depends on the 
ethnicity of population. In a meta-analysis assessing COMT association with PD, Domschke 
and colleagues found that the COMT 158 Val allele polymorphism is associated with PD in 
Caucasian samples with higher association in females in some cases, and an association of 
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the COMT 158 Met allele polymorphism with PD in Asian female samples (Domschke et 
al., 2007). The functional significance is the Val polymorphism has greater enzymatic 
activity than the Met polymorphism. In an fMRI study PD subjects with the COMT 158 Val 
polymorphism has greater activity in the right amygdala in response to fearful faces 
(Domschke et al., 2008), and have altered white matter connectivity compared with non-
carriers (Kim et al., 2013). Overall, the COMT polymorphism has a fairly strong association 
with PD, but the functional significance may be complicated.
Section 7: Strengths of Weaknesses of Animal Models of Adaptive and 
Pathological Panic States
As discussed in a 2001 NIMH workshop on the development of animal models of anxiety 
disorders, the relationship between existing animal models of anxiety and fear and clinical 
anxiety symptoms and syndromes needs much clarification (Shekhar et al., 2001). The focus 
of this special edition is on the development of translational animal models of panic 
disorder. Developing a single, ‘true’ model of a panic disorder that recapitulates all of the 
characteristics of the human disorder is highly unlikely for the following reasons: 1) PD 
diagnosis currently relies on self-reported symptom presentation (the accuracy of such 
patient self-report is a problem; e.g., objectively measured tachycardia not occurring during 
self-reports of tachycardia) and is not possible to assess in animals; 2) PA symptom 
presentation, frequency, and severity is fairly heterogeneous; 3) objective measures of 
physical symptom related activity prior to and during PAs also reveal heterogeneous 
responses; 4) neural circuits involved in naturally occurring PAs are not entirely clear; and 
5) the underlying pathology may be as heterogeneous as the PAs and is most likely an 
interaction between genetic vulnerability (trait-related) and complex environmental stress 
(state-related). Yet, as discussed in the following sections, animal models can help us best 
assess the mechanisms underlying candidate genes and neural circuits implicated in PD (see 
Figure 5). They can also help characterize normal adaptive behavioral and physiological 
responses to aversive situations such as: 1) conflict between risks and rewards; 2) where the 
animal is placed is previously threatening situation; and 3) finally where there is an 
immediate and imminent threat. There is some evidence that each of these three adaptive 
strategies may be related to pathology associated with generalized anxiety disorder, post-
traumatic stress disorder, and agoraphobia, and panic disorder, respectively. Animal models 
have other advantages as well. For instance, clinical studies related to PD are complicated 
for many reasons such as duration of illness; severity and frequency of PAs; previous and 
current pharmacotherapies; comorbidities; and differences in environment, diet, and racial/
ethnic and cultural background. In animal studies, many of these variables can be better 
controlled for, including the use of inbred strains to control for differences in genetic 
background. Molecular biology now also gives us the tools to genetically breed strains of 
rodents with high anxiety traits, or to assess the function of specific candidate genes (e.g, 5-
HTT and COMT) by knocking out or over-expressing the gene across development, or 
acutely silencing a gene with small interfering RNA, or with the use of conditional 
knockouts. Thus, we can potentially manipulate genes and/or environmental conditions and 
determine if these conditions lead to aberrant panic responses where animals display panic-
associated behavior and physiological responses similar to physical symptoms (e.g., 
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cardiovascular, respiratory, and thermal) following interoceptive stimuli such as NaLac and 
CO2 that provokes PAs in most PD subjects, or display these panic responses or aberrant 
fear-associated learning when in situations where panic responses have been provoked to 
model agoraphobia.
An important consideration in modeling panic and pathological panic is the validity of the 
model which relies on three major criteria. The first criterion is face validity, which is the 
degree in which the model measures something analogous to PAs. These can include 
behaviors that may indicate catastrophic fear such as explosive locomotor “flight” 
behaviors, escape from situations that are associated with risk (e.g., open arm on an elevated 
plus maze), hugging walls (thigmotaxis), or avoidance of brightly-lit areas. These types of 
behavioral assessments are fairly easy and high throughput, but an important consideration 
in modeling panic states and PA-like activity is the assessment of events surrounding the 
physical symptoms, which requires more exhaustive efforts of assessing autonomic 
cardiovascular and thermoregulatory events as well as respiratory responses. These 
techniques can be done in freely-moving, conscious rats using radiotelemetry probes 
surgically implanted into the abdomen or with pressure transducers inserted into the femoral 
artery for cardiovascular measures and whole body plethysmography for respiratory 
measures. The second criterion is postdictive and predictive validity. Postdictive validity is 
the sensitivity of a test to known panicolytic compounds such as SSRIs and 
benzodiazepines, or the ability of a known compound to block PA triggers such as CO2 or 
NaLac. Predictive validity is the ability of the test to predict efficacious panicolytic 
treatments. Finally, the most difficult type of validity is construct, which reflects the degree 
in which the animal model is related to the pathophysiological mechanism underlying PAs 
and PD. The subsequent sections will discuss animal models of adaptive panic and 
pathological panic vulnerability and the degree in which they meet the three criteria of 
validity (see also Figure 5 which outlines adaptive and pathological panic models, and their 
utility).
Section 7a. Animal models of adaptive panic, anxiety and fear memory
Another approach to expand our understanding of panic pathology utilizing animal models 
is to elucidate the neural and neurochemical circuits that mobilize normal ‘adaptive panic’ or 
risk assessment survival responses, which is in line with the mission of the NIH RDoc. The 
neurochemical circuits that regulate an animal’s ability to cope and effectively respond to 
aversive stimuli are related, but there are very important differences. Currently, anxiety 
states are typically assessed in “conflict anxiety” scenarios, which is when a threat is 
apparent, but not imminent, and is potentially also in conflict with a reward. An example of 
risk assessment would be to create the need to forage for food, at the risk of being eaten by a 
predator. This is effectively a “look before you leap” system where risk assessment plays a 
critical role in survival. Conversely, behavioral assessment of fear-associated memories also 
measures important adaptive responses to threat where an unconditioned threatening 
situation (e.g, predator attack) leads to a fear-conditioned memory. In rodents, this typically 
involves pairing a threatening, unconditioned stimulus such as a foot shock with a 
conditioned stimulus such as a tone or light. When the rodent is placed in similar 
environment and presented with only the conditioned stimulus (e.g., tone or light) there is a 
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strong behavioral freezing response. The advantage of these types of simple behavioral 
preparations is that the conditioning induces very reproducible freezing responses, and the 
neural circuits underlying this phenomenon (e.g., amygdala and prefrontal cortex) are being 
elucidated. However, this system is best linked to trauma-based pathology such as post-
traumatic stress disorder, but is a very important system linked to the development of ePAs 
and agoraphobia (conditioned fear responses when in situations where previous uPAs have 
occurred).
Yet, eliciting a true adaptive panic/defensive response typically involves putting an animal 
in a life-threatening situation (e.g., confrontation with a predator or an aggressive 
conspecific male). Unlike conflict and fear-associated behaviors which respectively assess 
uni-dimensional behaviors such as time spent in an area or freezing, assessing the panic 
response involves measuring multiple and complex somatic motor behaviors such as “flight” 
like increases in locomotion to attempt to escape the threat, specific patterns of 
vocalizations, and an array of physiological responses related to sympathetic mobilization 
and parasympathetic desensitization [e.g., cardiovascular (e.g., tachycardia, increases in 
blood pressure), and gastrointestinal (e.g., voiding and defecation) responses], as well as 
respiratory (tachypnea) and endocrine (HPA axis) responses. Although these types of 
models provide a wealth of data on normal ‘defense/panic’ circuits, and have been the main 
models that have helped map some of the brain circuits involved in fear and flight-or-fight’ 
responses, they provide much less information about the possible pathophysiology, or 
mechanistic approaches to understanding the origins of the human disease. Therefore, 
another approach that has been utilized is to determine if manipulations of those relevant 
circuits, genes, or neurochemicals can make animals vulnerable to displaying panic 
associated responses following interoceptive or exteroceptive triggers, and then also 
determine if there is evidence of agoraphobia.
Section 7b. Modeling panic through neural circuits implicated in panic in humans
As discussed in section 5d, there are striking similarities between cognitive and physical 
symptoms associated with PA and those resulting from deep brain stimulation of subcortical 
nuclei in the PeF and the DPAG of humans (see Figure 3), which in the PeF produces 
cognitive fear symptoms such as self-reported panic and fear of dying, as well as physical 
symptoms, such as tachycardia, increased blood pressure, and hyperventilation (Rasche et 
al., 2006; Wilent et al., 2010), thermal sensations, and parasthesias (Wilent et al., 2011). 
Stimulation of the DPAG elicits similar cognitive fear symptoms such as feeling of panic, 
intense anxiety, or fearing imminent death that are accompanied by physical symptoms such 
as chest pain, tachycardia, dyspnea, and thermal sensations (Nashold et al., 1969; Young, 
1989). Prior to these human studies, cat and rodent studies determined that these structures 
play a critical role as primary visceromotor systems, as well as playing a critical role in 
adaptive panic/fight or flight responses to imminent threats.
The notion that the PeF is a critical site for panic is not a new concept. In early studies by 
Bard and Hess, the hypothalamus was hypothesized to be a critical site for generating a 
coordinated panic defense reaction that consisted of behavioral and physiological responses 
appropriate for a “fight or flight” response (Bard, 1928; Hess and Akert, 1955), In the 1940s, 
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Hess and colleagues electrically stimulated posterior hypothalamic regions near the PeF and 
evoked strong autonomic and somatic responses resembling adaptive panic/defense 
reactions (e.g., increased blood pressure, piloerection, arching of back) (Hess and Brugger, 
1943). Further studies, conducted in rodents, electrically stimulated the PeF region which 
elicited cardiovascular and behavioral components of the “fight or flight” response including 
tachycardia, pressor responses, and tachypnea (Lynn, 1969; Markgraf et al., 1991), 
decreases in visceral blood flow and increases in hind limb blood flow (McCabe et al., 
1994) and “agitated” running proportional to stimulus intensity (Duan et al., 1996). 
Similarly, pharmacologically exciting the DPAG of cats (Carrive et al., 1987; Bandler and 
Carrive, 1988; Carrive et al., 1988) and rodents (Schenberg and Lovick, 1994; Bittencourt et 
al., 2004) elicits similar defensive responses as seen in the PeF, as well as tachycardia and 
increases in blood pressure.
It was later determined that both the PeF and DPAG were under tonic GABAergic 
inhibition, which is clearly observed by injecting a GABAA receptor antagonist into the PeF 
region and elicits escape and flight behaviors (Shekhar and DiMicco, 1987), anxiety-
associated behaviors in validated tests (Shekhar et al., 1990a) which are suggestive of 
catastrophic fear behaviors, as well as physical signs associated with PAs such as 
cardiorespiratory responses [e.g., hyperventilation, tachycardia, pressor response and 
thermal changes (Shekhar and DiMicco, 1987; Anderson and DiMicco, 1990; Shekhar et al., 
1990b; Soltis and DiMicco, 1992; Samuels et al., 2002)]. A key brain region that appears to 
regulate local GABAergic inhibition in this panic-generating site is the medial prefrontal 
cortex, and specifically ventromedial portion called the infralimbic cortex (ILC). Evidence 
for this first emerged in the 1920s, when Cannon and Britton found that decorticating cats 
produced a variety of defensive/panic behaviors (e.g., hissing, arching of back, and attempts 
to bite) and sympathetic nervous system responses (e.g., increases in blood pressure) to non-
threatening stimuli (Cannon and Britton, 1925). Bard and colleagues later discovered that 
transections of the cat forebrain produced hyperactive defensive responses, but if the 
transection were caudal to posterior regions of the hypothalamus where the PeF is located, 
then this response disappeared (Bard and Mountcastle, 1948). This led Bard to propose that 
the forebrain cortical regions suppress emotional responses to inconsequential or trivial 
stimuli by actions in the posterior regions of the hypothalamus, but when the organism is 
exposed to an imminent threat (e.g., a conspecific male or predator) then tonic inhibition of 
this region is removed and this produces a defensive ‘panic’ response. This hypothesis is 
supported by retrograde tracing in the PeF leading to robust labeling in ILC (Chen and 
Smith, 2003; Goddard et al., 2004; Johnson et al., 2008b). Since most of the projection 
neurons in the medial prefrontal cortex (mPFC) are glutamatergic, it is hypothesized that 
these neurons project to local GABAergic interneurons in the PeF to tonically inhibit their 
activity, which has been determined to be the case for mPFC projections to the amygdala.
Additional convergent evidence comes from ex vivo studies that have assessed cellular 
responses (i.e., immunostaining the protein product of the immediate early gene c-fos, which 
is expressed following activation of several second messenger receptor cascades) in brain 
regions following ethologically relevant exteroceptive threats [e.g., predator odor exposure 
(Dielenberg et al., 2001)], and interoceptive threats [e.g., 5 min exposure to gas containing 
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normoxic 20% CO2 (Johnson et al., 2005; Johnson et al., 2011), i.v. infusions of 0.5M 
NaLac (Johnson et al., 2008a; Johnson et al., 2008b)] or panicogenic pharmacological 
compounds [e.g., yohimbine, FG-7142, D-fenfluramine, and caffeine (Li and Rowland, 
1993; Singewald and Sharp, 2000; Singewald et al., 2003)] which is illustrated in Table 1. 
Further support comes from studies assessing polysynaptic connectivity of brain regions 
with peripheral cardiovascular and thermoregulatory targets in the rodent, which are 
respectively, the stellate ganglion (Jansen et al., 1995; Westerhaus and Loewy, 2001), a 
critical sympathetic ganglia for regulating cardiovascular activity, and the tail (Smith et al., 
1998), a critical site for heat dissipation.
Based on this collective work, Shekhar and colleagues chronically inhibited GABA 
synthesis in the PeF of rats (to effectively reduce cortical inhibition) which made them 
vulnerable to displaying panic-associated behaviors and cardiorespiratory responses to 
interoceptive stimuli that provoke PAs in humans (i.e., i.v. 0.5M NaLac infusions). 
Specifically, a GABA synthesis inhibitor (l-allylglycine:l-AG) is unilaterally infused into the 
PeF via an osmotic minipump, which increases anxiety-like behavior in the social 
interaction (SI) test, defensive burying test, and elevated plus-maze without altering baseline 
cardiorespiratory activity (Shekhar and DiMicco, 1987; Shekhar et al., 1996; Shekhar and 
Keim, 1997; Shekhar et al., 2006). However, following exposure to 0.5 M NaLac, these rats 
have increased anxiety-like behavior (greater than already present from l-AG infusion) and 
marked and rapid increases in cardiovascular functions (evidenced by either tachycardia 
and/or a pressor response), tachypnea and an increase in general locomotor activity (Shekhar 
et al., 1996; Shekhar and Keim, 1997, 2000; Johnson and Shekhar, 2006; Shekhar et al., 
2006; Johnson et al., 2008b; Johnson et al., 2010; Molosh et al., 2010). This model of panic 
vulnerability has been established for over 15 years, and has robust face, predictive, and 
construct validity [see review (Johnson and Shekhar, 2012)]. The model recapitulates many 
of the phenotypic features of human panic disorder thus providing face validity. The 
model’s predictive validity is demonstrated by panic responses to both panic-inducing 
agents (e.g. sodium lactate, yohimbine, and inhalations of CO2) and anti-panic effects of 
therapeutic agents such as alprazolam (Johnson et al., 2010; Shekhar et al., 2011) and group 
II metabotropic glutamate agonists (Shekhar and Keim, 2000). The construct validity of this 
model is supported by the fact that neural circuits of the PeF regulate behavioral and 
autonomic components of an adaptive panic/defense response in rats (Andreatini et al., 
2001), panic disorder subjects have reported deficits in central GABA activity (Goddard et 
al., 2001b) and pharmacological restoration of central GABA activity prevents panic attacks 
(Goddard et al., 2004), which is consistent with GABA reductions in key brain areas 
resulting in panic vulnerability as demonstrated with this animal model. This PeF model was 
also recently used to screen panicolytic properties of a novel GABA enhancer XBD173 drug 
and group II metabotropic glutamate transporter agonists [PeF model screening (Rupprecht 
et al., 2009) and (Shekhar and Keim, 2000)] which showed anti-panic properties in later 
clinical trials [clinical screening (Rupprecht et al., 2009) and (Schoepp et al., 2003; Kellner 
et al., 2005)].
Even though the PeF is a critical panicogenic site in humans, cats, and rats, the local 
neurochemical systems that mobilize this panic response had been elusive until 1998 when a 
novel neuropeptide system called orexin (also known as hypocretin) was determined to be 
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exclusively synthesized in neurons around the fornix in the poster regions of the 
hypothalamus. Initial work noted that dramatic loss of function of the orexin system 
disrupted sleep, and later clinical studies noted that central orexin tone and orexin neurons 
were dramatically reduced in narcoleptic patients. The orexin neurons were thought to be 
mainly located in the lateral hypothalamus, but Johnson and colleagues noted that they were 
mainly found in the PeF region. Based on this observation and orexin’s role in arousal and 
vigilance, in 2010 Johnson and colleagues determined that the orexin system was critical for 
panic responses in the PeF rat model of panic vulnerability, and that orexin-1 receptor 
antagonists were effective in attenuating panic responses provoked with interoceptive 
stimuli [e.g. i.v. 0.5M NaLac in panic vulnerability model (Johnson et al., 2010) and 
20%CO2 in healthy rats (Johnson et al., 2012c)], and panicogenic drugs (e.g., FG-7142 in 
healthy rats (Johnson et al., 2012a)). Since orexin’s discovery, more studies have 
demonstrated that this PeF orexin system is capable of mobilizing a coordinated adaptive 
panic/defense response (anxiety, cardiorespiratory, and endocrine components, and has 
particularly strong projections to anxiety and panic-associated circuitry such as the locus 
ceruleus [see review(Ferguson and Samson, 2003; Johnson et al., 2012b)]. A hyperactive 
orexin system is also linked to anxiety states in humans (Johnson et al., 2010).
Section 7c. Modeling genetic risk factors and assessing candidate genes associated with 
PD
Inbred rodents are one method of assessing heritability of anxiety-associated traits where 
some strains show higher anxiety-associated behaviors than other strains. For instance, some 
mice and rat strains have been bred to have high anxiety [e.g., S129/SvImJ mice, high 
anxiety bred rats (HAB)] and others low anxiety [e.g., C57BL/6J mice and low anxiety bred 
rats (LAB)]. Quantitative trait loci (QTL) analyses can then be utilized to identify 
associations between a specific phenotypic anxiety-associated behavior and a marker locus 
for sets of genes. These approaches have linked chromosome 1, 4, and 15 with increased 
anxiety-associated behaviors:chromosome 1 with exploration, chromosome 4 with 
locomotor activity, and chromosome 15 with avoidance [see review in (Perez et al., 2013)]. 
The disadvantage to this approach is that the anxiety traits will result from multiple genetic 
differences, rather than manipulating one specific gene such as a candidate gene associated 
with PAs and PD. Another approach is to utilize gene targeting to assessing candidate genes 
associated with PD or severity of PA. This can be done by silencing or “knocking out” a 
gene or over-expressing the protein product of that gene by inserting a transgene; in some 
cases, the human gene can be overexpressed. In knockout mice and rats, the gene is typically 
altered throughout development. More sophisticated gene targeting can control deletion or 
insertion of genes globally or in specific brain regions at specific time points during 
development using inducible techniques, such as the Cre/Lox system. Initially, the gene 
targets were chosen based on current pharmacological treatments for PAs and PD and 
candidate genes associated with those treatments (discussed in section 6)including 
GABAergic, serotonergic, and noradrenergic systems.
As discussed in section 6, overall there is evidence that loss of central GABAergic tone may 
contribute to PAs and PD, and a GAD1 polymorphism is associated with PD (Hettema et al., 
2005; Hettema et al., 2006). The GAD1 gene encodes the GAD67 enzyme, which is one of 
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two enzymes (GAD65 is the other) that synthesize GABA. Although Hettema and 
colleagues did not assess the effects of these polymorphisms on GABA activity, mice 
studies suggest that disruption of GABA’s synthetic enzymes does increase anxiety-related 
behaviors. In mice, targeted knockout of GAD67 is lethal (Condie et al., 1997); however 
mice with the GAD65 knockout, which would also alter GABAergic tone, does lead to 
increases anxiety-related behaviors in the open field test and elevated zero test, which 
assesses exploratory behaviors in potentially threatening regions that are brightly lit and 
away from walls or areas lacking walls (Kash et al., 1999). Transgenic knockouts of the 5-
HTT gene also increases anxiety-associated behaviors in mice; these mice avoid brightly lit 
arms in the elevated plus maze and bury fewer marbles in the defensive burying test (Line et 
al., 2011). Conversely, mice with over-expression of 5-HTT have reduced anxiety-
associated behaviors in these same tests (Line et al., 2011). Furthermore, the ability to 
extinguish fear associated memories is impaired in mice with loss of 5-HTT expression 
(Wellman et al., 2007), which suggests that disruption of 5-HTT activity in humans could 
predispose them to ePAs and/or agoraphobia. Loss of COMT gene function due to knockout 
leads to more avoidance behavior in a light-dark box test, but only in female mice (Gogos et 
al., 1998), which models aspects of the higher incidence of PD in women. Overall, these 
genetic manipulations in mice do support a role for these genes as important components of 
anxiety regulation. Yet, it is important to note that these targeted genetic approaches are 
designed to assess loss of function (e.g., knockout), or gain of function (e.g., over-
expression).
A more desirable approach would be to genetically recreate the polymorphism then 
determine the biochemical and behavioral consequences of these polymorphisms. As 
discussed in section 6, the 5-HTT s-allele polymorphism which reduces transcriptional 
efficiency (Little et al., 1998), is associated with increased anxiety traits (Lesch et al., 1996) 
and is strongly associated with the severity of panic symptoms in PD (Lonsdorf et al., 2009). 
As mentioned previously, knockout mice with complete loss of 5-HTT have increased 
anxiety-associated behaviors. A more suitable model of the reduced efficiency of the 5-HTT 
in humans are rats with a heterozygous null mutation of the 5-HTT, which similarly reduces 
transcriptional efficiency by approximately 50%, and are resistant to SSRIs (Homberg et al., 
2007). Similar to mice studies, rats with complete loss of the 5-HTT gene have increased 
baseline levels of anxiety-associated behaviors (Olivier et al., 2008; Joeyen-Waldorf et al., 
2009; Johnson et al., 2012d). Yet, baseline levels of anxiety-associated behaviors in rats 
with the heterozygous null mutation of the 5-HTT gene are normal compared to wildtype 
controls (Joeyen-Waldorf et al., 2009; Johnson et al., 2012d). However, in a standard fear 
conditioning procedure using shock as the unconditioned stimulus and tone as the 
conditioned stimulus, the rats with the heterozygous null mutation of the 5-HTT gene 
display enhanced acquisition of fear-associated freezing behaviors and are resistant to 
extinction of fear on subsequent days when only the tone was presented as a cue (Johnson et 
al., 2012d). These rats also have increased excitatory tone in the amygdala at baseline 
(Johnson et al., 2012d). These preclinical data are consistent with clinical studies mentioned 
in section 6 showing that humans with this polymorphism have enhanced reactivity of the 
amygdala (Hariri et al., 2002; Heinz et al., 2007), and better acquisition of fear conditioning 
(Garpenstrand et al., 2001) than those with only long alleles. Overall, this provides further 
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evidence that reduced 5-HTT efficiency in humans may predispose them to ePAs and or 
agoraphobia. Future studies of 5-HTT knockout and heterozygous null mutations in rats are 
needed to assess anxiety and panic-associated behavioral and autonomic responses to 
exteroceptive and interoceptive stimuli that trigger PAs in PD subjects. The utilization of 
site- and development-specific knockout rats would also permit a more elegant delineation 
of specific contributing factors to the development of anxiety phenotypes.
Section 7d. Modeling risk factors such as early life stress and gender
As discussed in previous sections, there is evidence that significant early life stress (e.g., 
maternal deprivation) may decrease functional connectivity of the PFC with subcortical 
panic-generating circuits which is associated with increased anxiety (Milad and Quirk, 
2012). Many significant early life stress events such as child abuse, neglect, or loss of 
parents due to death or abandonment are receiving much attention as contributing factors to 
anxiety disorders and pathology associated with trauma such as PTSD. Previous trauma as a 
child or trauma as an adult could be an additional predisposing factor contributing to PAs 
and PD that may be comorbid with a previous diagnosis such as separation anxiety disorder 
or current diagnoses such as PTSD [see review by (Gittelman and Klein, 1984)]. In regards 
to animal modeling, early life stress can be done using methods such as maternal separation 
or during adolescence using social defeat paradigm (where a smaller male is placed in a cage 
with an aggressive larger animal) to model bullying and behavioral despair. Currently, there 
is very little known about how these types of traumatic events contribute to panic 
vulnerability in rodents. Another major gap in rodent studies is that the vast majority of 
experiments in anxiety are conducted in males and not females [out of 10,000 assessed 
experiments, 9,397, or 94%, were done in males (Griebel and Holmes, 2013)]. Thus, there is 
a pressing need for studies to assess the effects of sex and traumatic events (that occur 
during early life, adolescence, and adulthood) on anxiety and panic-associated behaviors as 
well as panic vulnerability to exteroceptive and interoceptive stimuli where autonomic, 
respiratory, and endocrine measures are assessed.
Section 8: Gaps in knowledge and Future Direction Conclusion
Based on the above discussion, there are a numerous gaps in our understanding of the 
pathophysiology of PAs and PD. One major gap in knowledge is understanding the 
characteristics associated with early episodes of uPAs, especially PAs prior to frequent 
recurrence or onset of agoraphobia. Such studies are difficult to conduct due to obvious 
difficulties of timing and being able to monitor uPAs in real time. However, with increasing 
application of mobile technologies (e.g. smartphone apps) to monitor a wide range of patient 
phenotypes and biochemical and physiological measurements, such studies will provide 
critical information that is needed to understand the pathophysiology of PD onset. There is 
also great lackdisease biomarkers that predict patient and high risk groups. Studies of 
cognitive-emotional, autonomic, respiratory, endocrine tone differences, as well as imaging, 
between control and high risk first degree relatives of PD subjects are also necessary to 
better define the spectrum of disease phenotypes. Similarly, detailed studies of laboratory-
induced PAs in first degree relatives of PD subjects would be highly informative. Although 
a few small studies have utilized ambulatory monitoring of PD subjects, there is a need for 
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clinical assessment of PAs in relatively non-threatening situations and in situations that are 
more aversive, and/or where PAs have occurred previously. At the systems and genetic 
levels, we need more information on the biochemical consequences of more common 
genetic polymorphisms associated with PAs and PD, as well as rodent work involving 
targeted gene disruptions and knock-ins similar to polymorphisms associated with PAs and 
PD. Finally, we need to systematically evaluate novel pathways and mechanisms, utilizing 
models that have robust validity for aspects of PD phenotype.
Another effort that is underway, under the leadership of the National Institute of Mental 
Health in the United States, is the development of Research Domain Criteria (RDoc), which 
hopes to provide some guidance on understanding brain mechanisms-based approaches for 
psychiatric disorders. This is a bold and broad vision, and specifically could create a new 
approach to understanding anxiety disorders, not as categorical and discrete disease entities 
each with unique ‘locus’ of pathology, but more as complex phenotypic expressions of 
disturbances in fundamental brain network functions. As this approach evolves, and more 
and more functional and molecular data get mapped on to brain networks in normal and 
disease processes, the definitions of different ‘subtypes’ of PAs and PDs will become richer. 
Currently, the RDoc process is in its early stages, and much foundational concepts are yet to 
be defined for wide range of psychiatric symptoms. For example, within the RDoc, the 
concept of PAs is essentially undefined and at best falls in one of the negative domains, 
within the ‘construct’ of acute threat. The most commonly cited approach to studying this 
domain is utilizing concepts such as fear-conditioned freezing or startle. Simply taking these 
models at face value would lead one to assume that all PAs would routinely involve ‘fear’ 
circuits centered on the amygdala, and its upstream and downstream connections. Yet, it is 
very clear that many forms of uPAs (early spontaneous PAs) and some challenge-induced 
PAs (e.g., CO2-induced PAs) do not activate the amygdala and can occur in subjects with 
bilateral amygdala lesions. Thus, there may well be elements of sub-constructs within 
construct of ‘acute threat’ under the ‘negative valence systems’ that need further delineation, 
such as a) perceived or explicit threat and b) interoceptive or non-perceived threat networks 
which lead to the classic PAs. Thus, both at the conceptual level and at the data-gathering 
level, many gaps exist in our understanding of PD. We hope this review provides a brief 
overview of the current state of data, and the gaps in our knowledge, about PAs and PD, and 
an impetus for much work that lies ahead.
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Highlights
1. Panic Disorder and Panic Attack Symptoms and Signs (DSM-III through V)
2. Biological Basis of Unexpected and Expected Panic Attacks
3. Panic Attacks Triggers – Laboratory-induced and Naturally Occurring
4. Neurochemical Circuits Implicated in Adaptive and Pathological Panic
5. Animal Models of Adaptive and Pathological Panic States
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Figure 1. 
This bar graph represents the number of minor and major panic attacks that occur 
throughout the day from 97 PD subjects and from a total number of ambulatory monitored 
panic attacks. Major attacks are shaded red and minor attacks are shaded pink. Gray 
background shading represents typical time for sleep and white background represents 
typical wake times of an adult. Adapted and reproduced with permission from (de Beurs et 
al., 1994)
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Figure 2. 
a) Cumulative incidence of panic attacks and panic disorder over early life development 
until early adult stage in male and females. Figure adapted from (Reed and Wittchen, 1998) 
with permission. b) Note that PAs and PD begin to develop during adolescence when 
prefrontal cortical remodeling of local glutamatergic and GABAergic synapses is occurring. 
In support of a cortical developmental contribution to PAs and PD pathology, gene x 
hormone x environmental stress interactions may collectively contribute to abnormal PFC 
development, and loss of tonic inhibition of subcortical panic generating brain regions such 
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as the perifornical hypothalamus and dorsal periaqueductal gray, which could contribute to 
the onset of PAs and PD. Figure 1b adapted from figure 1 in (Insel, 2010) with permission.
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Figure 3. 
Represents a hypothetical graphical illustration of rostrocaudal coronal sections from the 
human brain that are relevant to panic disorder (PD) and panic attacks (PAs) with: sensory 
input centers indicated by green shading; hypofrontality indicated by blue shading; and brain 
regions implicated in cognitive catastrophic fear and physiological components (e.g., 
cardiovascular, respiratory, thermal) responses indicated in red. Illustrations were generated 
from histological coronal brain sections posted on the “Brain Biodiversity Bank” from 
Michigan State University Website, which was supported by the National Science 
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Foundation Grants 0131267, 013182, and 0131028. Abbreviations are the following: 5-HT, 
serotonin; A, adrenergic; A3V, anteroventral 3rd ventricle region; ACh, acetylcholine; aCC, 
anterior cingulate cortex; BLA, basolateral amygdala; BNST, bed nucleus of the stria 
terminalus; C1, C1 adrenergic neurons; CeA, central amydala; CVO, circumventricular 
organ; DA, dorsal hypothalamic area; DMN, dorsomedial hypothalamic nuclei; DMV, 
dorsal motor nucleus of the vagus; DPAG, dorsal periaqueductal gray; DRn, dorsal raphe 
nucleus; LA, lateral amygdala; LC, locus ceruleus; MeA, medial amygdala; NA, 
noradrenergic; nTS, nucleus of the solitary tract; ORX, orexin; OVLT, organum vasculosum 
lamina terminalis; PBN, parabrachial nucleus; RPa, raphe pallidus.
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Figure 4. 
Represents a hypothetical illustration of potential interoceptive and exteroceptive triggers of 
PAs and proposed pathways and brain regions that are important sensory and relay sites for 
components of PAs. When applicable, neuropeptide and neurotransmitter systems associated 
with each brain region are listed below in parentheses.
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Figure 5. 
a) the 1st Column represents methods of inducing panic states in normal rats (blue shaded 
region)or panic vulnerable rats (red shaded region) by interoceptive, or exteroceptive 
panicogenic challenges, or by deep brain stimulation of panicogenic brain regions. The 2nd 
column represents assessments of panic with behavioral tests only, or in combination with 
autonomic and or respiratory assessments. The scale to right represents the level of difficulty 
of the experiment (thoughput) and the level of translational validity. b) represents the utility 
of rodent panic models.
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